Judy E. Garber, MD, MPH

Susan F. Smith Chair, Dana-Farber Cancer Institute

Chief, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute

Professor of Medicine, Harvard Medical School

Dr. Garber is the Susan F. Smith Chair and Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. She conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. Dr. Garber is also a leader in research into the characteristics and treatment of triple negative breast cancer, the most common form in women with *BRCA1* mutations and an expert in Li-Fraumeni Syndrome. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.

Dr. Garber is a past president of the American Association for Cancer Research (AACR). She served on the National Cancer Advisory Board of the National Cancer Institute and was elected into the American Society of Clinical Investigation, the American Association of Physicians and the National Academy of Medicine. She serves as the Scientific Director of the Breast Cancer Research Foundation and is a past chair of the Breast Cancer Research Foundation Scientific Advisory Board. She is an ASCO Statesman and a Fellow of the AACR Academy, and was its first president.

CURRICULUM VITAE

Date Prepared: 4 March 2022

Name: Judy Ellen Garber, M.D., M.P.H.

Office Address: Dana Farber Cancer Institute
450 Brookline Avenue, Boston, MA 02215

Home Address: 199 Ward Street, Newton, MA 02459

Work Phone: (617) 632 2282

Work E-Mail: judy_garber@dfci.harvard.edu

Work FAX: (617) 632 4088

Place of Birth: Atlantic City, New Jersey

Education

1976	B.A. (highest honors)	Liberal Arts	University of Virginia, Charlottesville, VA
1981	M.D.	Medicine	Yale University School of Medicine New Haven, CT
1981	M.P.H.	Epidemiology of Chronic Disease	Yale University School of Medicine

Postdoctoral Training

6/1981-6/1982	Intern	Medicine	Brigham and Women's Hospital, Boston, MA
6/1981-6/1988	Clinical Fellow	Medicine	Harvard Medical School, Boston, MA
7/1982-6/1984	Resident	Medicine	Brigham and Women's Hospital
7/1984-6/1985	Asst Chief Resident	Medicine	VA Medical Center, Brockton, MA
7/1985-6/1985	Clinical Fellow	Hematology	Brigham and Women's Hospital
7/1985-6/1988	Fellow	Medical Oncology	Dana-Farber Cancer Institute, Boston, MA
7/1986-6/1989	Fellow	Cancer Epidemiology	NCI/Dana-Farber Cancer Institute
7/1989-6/1990	Fellow	Cancer Epidemiology & Biostatistics	NCI/Dana-Farber Cancer Institute

Faculty Academic Appointments

1988-1992	Instructor	Medicine	Harvard Medical School
1992-2000	Assistant Professor	Medicine	Harvard Medical School
2000-2011	Associate Professor	Medicine	Harvard Medical School
2011-	Professor	Medicine	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

7/1988-	Active Staff	Medical Oncology	Dana-Farber Cancer Institute
7/1988-	Associate Physician	Medicine	Brigham and Women's Hospital

Other Professional Positions

National

1996 – 1999	Genetics Advisory Board member	National Surgical Adjuvant Breast and Bowel Project (NSABP) Pittsburgh, PA
1997	Program Leadership Retreat and External Review Panel member	CTRC Research Foundation, San Antonio Cancer Institute, San Antonio, Texas
1998	Advisory Panel member:	Breast Cancer Prevention Trial National Cancer Institute and NSABP Chantilly, VA
1999 – 2002	Advisory Board member	Susan G. Komen Breast Cancer Foundation, Dallas, TX
2004 - 2006	Medical Advisory Board member	Young Survival Coalition, New York, NY
2006 - 2008	Advisory Board member	Braman Family Breast Cancer Center, University of Miami, Miami, FL
2006 – 2012	External Advisory Board member,	SPORE in Breast Cancer UT MD Anderson Cancer Center Houston, TX
2007	Chair, External Advisory Board	Racial Disparities in the Initiation and Intensity of Adjuvant Therapy for Breast Cancer Study, Columbia University,

		New York, NY
2008 - 2014	Scientific Advisory Board member	The Breast Cancer Research Foundation, New York, NY
2007 – 2012	Advisory Committee Member	Board of Scientific Counselors National Cancer Institute, Bethesda, MD
2008	Shapira Grant Advisory Board member	University of Pittsburgh, Pittsburgh, PA
2009 – 2011	External Advisory Board member	Fox Chase Cancer Center, Philadelphia, PA
2012	External Advisory Board member,	SPORE in Breast Cancer, Johns Hopkins Cancer Center, Baltimore, MD
2013	External Advisory Board member,	Basser Center for BRCA Biology University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
2013 - 2018	Member,	National Cancer Advisory Board Presidential Appointment, National Cancer Institute, Bethesda, MD
2014 - 2016	Member,	Council of Councils, Representing the NCAB National Institutes of Health Bethesda, MD
2016	Committee on the Evidence Base for Genetic Testing,	National Academy of Medicine, Washington, DC
2014- 2016	Chair, Scientific Advisory Board	Breast Cancer Research Foundation, New York, NY
2016	Scientific Director	Breast Cancer Research Foundation, New York, NY
2016- 2020	Medical Advisory Board member	Bright Pink, Chicago, IL
2017	External Advisory Board	MD Anderson Cancer Center,

		Houston, TX
2017-2019	Member, External Advisory Board,	Herbert Irving Cancer Center Columbia University, New York, NY

International

2007	Advisory Board member	KConFab, Melbourne, Australia
2010 – 2013	International Scientific Advisory Board member	French National Cancer Institute (INCa) Paris, France

Major Administrative Leadership Positions

Local

1991 – 2010	Director, Cancer Risk and Prevention Program	Dana-Farber Cancer Institute
2006 – 2019	Co-Chair, IRB Panel D	Dana-Farber Cancer Institute
2005 –	Co-Director, CME Course	HMS/DFCI/BWH Cancer Center & MGH Cancer Center Conference: Breast Cancer Current Controversies
2010 -	Director, Center for Cancer Genetics and Prevention	Dana-Farber Cancer Institute
2012 – 2015	Member, Strategic Planning Adult Clinical Care	Dana-Farber Cancer Institute
	Member, Strategic Planning Adult Clinical Research	Dana-Farber Cancer Institute
2012 – 2014	Member, MedSeq Data Safety Monitoring Board	Brigham and Women's Hospital
2012- 2015	Co-Chair, Cancer Genomics Evaluation Committee	Dana-Farber Cancer Institute
2012- 2014	Member, DF/HCC Clinical Sciences Coordinating Committee	Dana-Farber/Harvard Cancer Center
2013-	Member, Executive Committee for Clinical Programs	Dana-Farber Cancer Institute
2013-	Member, Executive Committee for	Dana Farber Cancer Institute

	Clinical Research	
2017-	Chief, Division of Cancer Genetics and Prevention	Dana Farber Cancer Institute

Committee Service

2021	Breast Cancer MDACC Moon Shots Annual Disease Site Scientific Advisory Board (SAB)	

Local

1987 – 1990	Joint Committee on the Status of Women, member	Harvard Medical School
1996 – 2000	Genetics Advisory Board member, Nurses Health Study	Harvard School of Public Health Boston, MA
2004 – 2008	Center of Excellence on Women's Health Member, Steering Committee Member, Research Committee	Harvard Medical School
2000 – 2002	Genetics Advisory Committee member	Harvard Medical School
2007 – 2008	Human Genetics Advisory Committee member	Harvard Medical School
2010 –	Member, Personalized Cancer Medicine Partnership Steering Committee	Dana-Farber Cancer Institute
2010 –	Member, Personalized Cancer Medicine Partnership Executive Committee	Dana-Farber Cancer Institute
2010 –	Member, Division of Population Sciences Executive Committee	Dana-Farber Cancer Institute
2011 – 2013	Member, CRI Research Concept Review Committee	Dana-Farber Cancer Institute

2011	Member, DF/HCC Planning Committee, SPORE in Breast Cancer	Dana-Farber/Harvard Cancer Center
2012- 2014	Member, Emmanuel College Science Advisory Council	Emmanuel College, Boston, MA.
2012	Member, Ad Hoc Search Committee Professor of Medicine to serve as Director of Hematology Malignancies Program, MGH	Harvard Medical School
2013	Member, Ad Hoc Search Committee Chief, Clinical Genetics Branch	National Cancer Institute Bethesda, MD
2014- 2019	Promotions Committee, Department of Medicine	Brigham and Women's Hospital Harvard Medical School

National

1995 – 1996	Cancer Genetics Working Group Co-Chair, Education Subgroup	National Cancer Institute, Bethesda, MD
1995 – 1996	Cancer Centers Review Panel member	National Cancer Institute
1995 –	1995–2006 Solid Tumor Correlative Science Committee 1998–2001 Member, Cancer Control Committee 2001–2006 Chair, Prevention Subcommittee 2006– Member, Cancer Prevention Committee	Cancer and Leukemia Group B, Chicago, IL
1996 – 1998	Genetics Working Group Co Chair, Education Subcommittee	National Action Plan on Breast Cancer US Dept. of Health, Washington, DC
1997	Cancer Genetics Working Group, member	National Cancer Institute
1997	Breast Cancer Progress Review Group Co-Chair, Breast Cancer Genetics Subcommittee	National Cancer Institute
1999-	Breast Cancer Prevention Committee member	National Comprehensive Cancer Network Fort Washington, PA

2000 – 2004	Early Detection Research Network 2000 – 2003 Steering Committee member; 2004, Consulting Committee	National Cancer Institute
2001	Gynecologic Cancers Progress Review Group: Co-Chair, Clinical and Molecular Genetics Sub-Committee	National Cancer Institute
2001	Breast Cancer Progress Review Group Molecular Genetics Subcommittee member	National Cancer Institute
2003	Clinical Genetics Branch Site Visit Team member	National Cancer Institute
2004	Sarcoma Progress Review Group member	National Cancer Institute
2004 –	Abstract Review Group member	San Antonio Breast Conference, San Antonio, TX
2007	Stratified Cancer Prevention Group for Identifying Predictive Epithelial Markers for Breast Cancer Risk and Risk Reduction member	National Cancer Institute
2007	NSABP P-4 Trial Assessment Group member	National Cancer Institute
2008	Planning Committee member, NIH State-of-the-Science Conference on Ductal Carcinoma in Situ	Johns Hopkins University, Baltimore, MD
2009	EDRN Site Visit member	Fox Chase Cancer Center, Philadelphia, PA
2009 –	Scientific Advisory Committee	Love/Avon Army of Women, Santa Monica, CA
2010	President's Cancer Panel, Delegate	American Association for Cancer Research, Philadelphia, PA
2010 – 2014	Scientific Advisory Committee	Susan G. Komen for the Cure Foundation, Dallas, TX

2013 -	Steering Committee	California Breast Cancer Prevention Initiatives, Oakland, CA
2014-	External Advisory Board, Moonshot in Triple Negative Breast Cancer	MD Anderson Cancer Center, Houston, TX
2016-	External Advisory Board	MD Anderson Cancer Center, Houston, TX
2017-	AACR Annual Meeting Clinical Trials Committee	American Association for Cancer Research, Philadelphia, PA
2017-	Directors Advisory Committee	Rutgers Cancer Institute of New Jersey New Brunswick, NJ
2017-	Kripke Legend Award Selection Committee	MD Anderson Cancer Center, Houston, TX

International

1996 –	International Breast Cancer Study Group (IBCSG), Data Safety Monitoring Committee Member	International Breast Cancer Study Group Bern, Switzerland
1998 – 2009	Data Safety Monitoring Committee (BIG 1-98 Trial) Member 2006 – 2009, Chair	Breast International Group, Brussels, Belgium
2002 –	Data Safety Monitoring Committee, HERA Trial, Member	Breast International Group Brussels, Belgium
2004 –	Steering Committee member, ExCel Trial (MAP-3)	National Cancer Institute of Canada Canadian Institutes of Health Research, Toronto, Canada
2006	Planning Committee member, St. Gallen 4th International Conference on Cancer Prevention	St. Gallen Oncology Conferences St. Gallen, Switzerland
2007 –	Data Safety Monitoring Committee of the ALTTO and neo-ALTTO Trials, Member	Breast International Group,
2008	Planning Committee St. Gallen 5th International Conference on Cancer Prevention, Member	St. Gallen Oncology Conferences

2008 - 2011	Data Monitoring Committee of the SOLE Trial, Chair	Breast International Group,
2013	Review Panel, Ontario Institute for Cancer Research, Toronto, Canada	OICR

Professional Societies

National

1994 – American Society of Clinical Oncology

1996 – 1999	Member, Cancer Genetics Task Force
1998	Member, Writing Committee for Cancer Genetic Predisposition Testing Curriculum, v. I
1999	Chair, Cancer Genetics and Tumor Biology Program Committee
2000	Member, Cancer Genetics Subcommittee Advisory Committee
2000	Member, Cancer Genetics Education Program Committee
2002 – 2003	Member, Taskforce on Cancer Prevention
2003 – 2006	Member, Cancer Prevention Committee
2004 – 2009	Member, Grants Selection Committee
2005 – 2006	Chair, Cancer Prevention Committee
2008 – 2009	Chair, Grants Selection Committee
2008 –	Member, Cancer Education Committee – Genetics Track
2013-	Co-Chair, Cancer Genomics for the Clinician Symposium, Annual Meeting
2014-2016	Member, Awards Committee

1994 – American Association for Cancer Research

1998	Member, Committee on Chemoprevention
1999	Program Committee member
2001 – 2002	Member, Cancer Prevention: 2002 Annual Meeting Planning Committee
2004	Chair, Genetics Program Planning Committee
2007 – 2008	Member, Selection Committee – AACR Price for Translational Research
2007 – 2009	Member, Committee on Special Conferences
2007 – 2008	Chair, AACR/BCRF Breast Cancer Review Program Panel
2007 – 2010	Member Board of Directors (Elected)
2008 – 2010	Planning Committee member, San Antonio Breast Cancer Symposium University of Texas at San Antonio Scientific Symposia Group and AACR, San Antonio, TX
2009	Member, Selection Committee – 2010 Lifetime Achievement Award
2010	Member, Board of Directors
2011 -	Member, Scientific Policy and Legislative Advisory Committee
2010 – 2011	President-elect
2011 – 2012	President
2013	Chair, Margaret Foti Award Selection Committee
2013-	Foundation Board of Trustees

2018- Inaugural AACR Academy President-Elect

1994 – American Society of Preventive Oncology

1990- American Society of Human Genetics
1995 Member, Breast Cancer Genetic Testing Evaluation

American Cancer Society, Atlanta, GA
1997 Co-Chair, National Conference on State of the Art in Cancer Genetics: Societal and Clinical Implications of DNA Testing
1998 Co-Chair, National Conference on Cancer Genetics

2001 – American Society for Clinical Investigation (Elected)

2007 - American College of Obstetricians and Gynecologists District II/NY
Hereditary Breast and Ovarian Cancer Task Force member

2012 – Association of American Physicians (Elected)

2016- American Clinical and Climatological Association

Grant Review Activities

Local

2008	Harvard University BIRCWH Training Grant Program	Member, Grant Review Panel
2012	Dana-Farber / Harvard Cancer Center Men's Collaborative	Member, Grant Review Committee
2011 -	Dana Farber Women's Cancers SPORE development project review	Member, Grant Review Committee
2012-	Dana Farber Susan F. Smith Center Translational projects	Member, Grant Review Committee

National

1994	Department of Defense, Washington, DC	Member, Epidemiology Study Section Breast Cancer Program
1996	National Cancer Institute	Member, Ad Hoc Review Panel, Behavioral Medicine Study Section

1997-2000	University of Pennsylvania, Philadelphia, PA	Member, P21 Grant Advisory Board, Genetic Approaches to Breast Cancer Biology and Treatment
1998	National Cancer Institute	Member, Ad hoc Review Panel, Informed Consent RFA
1999	National Cancer Institute	Member, Ad-hoc PO1 Review Panel, Breast Cancer Genetics and Epidemiology
2000	National Cancer Institute	Member, Ad-hoc Review Panel, Breast Cancer Family Registries
2005	National Cancer Institute	Member, Mutagenesis Cluster Review Panel
2005	National Cancer Institute	Member Scientific Review Group-Subcommittee E (P01)
2007	National Cancer Institute	Member, Ad Hoc Review Panel Epidemiology of Cancer (EPIC) Study Section: Health of the Population (HOP) Integrated Review Group
2007	AACR, Philadelphia, PA	Chair, Breast Cancer Research Grant Review
2007 – 2008	American Society of Clinical Oncology, Alexandria, VA	Chair, ACRA Grant Review Panels: Breast Sarcoma Hematological Malignancies
2008 –	Susan G. Komen for the Cure Foundation, Dallas, TX	Chairman, Grant Review Committee: Genetics, Genomics and Biomarkers Postdoctoral Awards
2008 – 2009	National Cancer Institute	Ad Hoc Member, Epidemiology of Cancer (EPIC) Study Section
2009	National Institutes of Health	Reviewer, New Innovator Award (NIA) Program
2009	CTRC – AACR San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT San Antonio San Antonio, TX	Co-Chair, Scholarship Selection Committee

	AACR, Philadelphia, PA	
2010	National Cancer Institute	Member, EPIC Special Emphasis Panel
2010	National Cancer Institute	Member, Breast Cancer Biology Special Emphasis Panel
2011-	Susan G. Komen for the Cure	Member, Panel IIR Developmental Therapeutics
2014-	Susan G. Komen for the Cure	Member, Post Doctoral Fellows in Breast Cancer review panel
2014 - 2020	National Cancer Institute National Institutes of Health	Member, National Cancer Advisory Board Member, Council of Councils

International

2004	European Commission, Brussels Belgium	Member, Grants Review Panel, 6th EU Framework Belgium Program of the European Community for Research: Familial Cancers
2005	Jacqueline Seroussi Memorial Research Foundation, Jerusalem, Israel	Member, Grants Review Panel
2007	Breakthrough Breast Cancer Collaborative Grants Program, London. UK	Member, Grants Review Panel

Editorial Activities

Ad Hoc Reviewer

New England Journal of Medicine
Journal of the American Medical Association
Journal of the National Cancer Institute
Journal of Clinical Oncology
Cancer Epidemiology, Biomarkers & Prevention
Cancer Research
Clinical Cancer Research
Breast Cancer Research and Treatment
Cancer
Cancer Discovery
PLOS Genetics

Editorial Boards

1997 – 2000	Member	Oncology Reviews

2000 – 2008	Member	Cancer Epidemiology, Biomarkers & Prevention
2001 –	Consulting Editor	The Breast
2002 -	Associate Editor	Familial Cancer Genetics
2004 – 2009	Associate Editor	Harvard Women's Health Watch
2004 – 2008	Senior Editor	Clinical Cancer Research
2005 – 2008	Associate Editor	Journal of Clinical Oncology
2008 -	Senior Editor	Cancer Prevention Research

Honors and Prizes

1976	Phi Beta Kappa	University of Virginia	Academic Achievement
1981	Alpha Omega Alpha	Yale Medical School	
1988	Travel Award	American Association for Clinical Research	Scholars – in – Training
1990	Travel Award	American Society of Clinical Oncologists	Scholars – in – Training
1990	Travel Award	American Association for Clinical Research	Scholars – in – Training
1997 – 2000	Scholar in Clinical Research	The Dyson Foundation Millbrook, NY	Clinical Research
2004	John A. DeQuattro Memorial Lecture	Manchester Memorial Hospital, Manchester, CT	Research
2004	Roche Lectureship	Robert Wood Johnson Medical School, New Brunswick, NJ	Research
2006	Linda Fenner Memorial Lectureship	Linda Fenner Society, Jerusalem	Research
2007	Tisch Award	Dana-Farber Cancer Institute	Understanding and Treatment of Triple Negative Breast Cancer
2008	Phyllis T. Bodel Lectureship	Yale School of Medicine, Department of Internal Medicine, New Haven, CT	Distinguished women physician scientists

2008	ASCO Statesman Award	American Society of Clinical Oncologists	Extensive service to the society
2008	Keynote Address	Leura VI International Breast Conference, Sydney Australia	Research
2009	Pappamarkou Lecture	Memorial Sloan-Kettering Cancer Center, Gynecologic Oncology Service and Breast Service, NY, NY	Research
2009	Great Teachers at NIH Grand Rounds	National Institutes of Health/ The Johns Hopkins University School of Medicine	Education
2009	Salvatore Venuta Lecture	Universita degli Studi "Magna Graecia" di Cantanzaro Advanced Course on Hereditary Breast and Ovarian Cancer, Catanzaro, Italy	Achievement
2009	Claire W. and Richard P. Morse Research Award	Dana-Farber Cancer Institute	Excellence in Clinical Research
2010	Axia Award	Hellenic Women's Club	Achievement
2011	Bernard Fisher Lecture	University of Pittsburgh School of Medicine, Department of Surgery	Distinguished Service
2012	Daniel G. Miller Endowed Lecture in Cancer Prevention	Weill-Cornell Medical School	
2013	Fellow of the AACR Academy	American Association for Cancer Research	Excellence in cancer research
2017	Margaret L. Kripke Legend Award & Lecture	MDAnderson Cancer Center	Dedication to enhancing careers of women in cancer science and cancer medicine
2017	Joseph H. Burchenal Award and Lecture	American Association for Cancer Research	Outstanding achievements in clinical cancer research

2017	Umberto Veronesi IEO Breast Cancer Award	European Institute of Oncology	Breast cancer genetics
2017	Susan F. Smith Chair	Dana-Farber Cancer Institute	Endowed chair
2018	2018 Giant of Cancer Care in Prevention/Genetics	OncLive	Oncology Award
2018	Human Cancer Genetics Program Commemorative Medal and Lecture	The Ohio State University	
2018	Connie Johnson Memorial Lecture	The Garvan Institute, Sydney Australia	
2019	ASCO-ACS Award	ASCO	Outstanding Contributions
2021	Franco Muggia Award		
2021	Distinguished Scientist Award	Association of American Cancer Institutes	
2021	Brinker Award	Susan G. Komen	Clinical Research

Report of Funded and Unfunded Projects

Past

1991-1994 International Registry for Families with Li-Fraumeni Syndrome

NIH 263-MD-129945
PI

1992-1994 Linkage and Mapping of Breast Cancer

NIH/NCI RO1 CA57601
Co-Investigator

1992-1994 Premalignant Lesions and Breast Cancer Risk

NIH/NCI P20 CA58203
PI

1993-1995 Risk Perception and Decision-Making in Women at High Risk for Breast Cancer
Massachusetts Department of Public Health Breast Cancer Research
Co-Investigator

1993-1997 Counseling Women at Risk for Breast Cancer

NIH/NCI RO1 CA63605
Co-Investigator

1994-1999 A Predictive Testing Program for P53 Mutations in Li Fraumeni Syndrome

NIH/NHGRI RO1 HG00725
PI

1994-2001 Dissemination of a BRCA 1 Predisposition Testing Program

NIH/NHGRI (RO1 HG01244)
PI

1995-1999 Cooperative Family Registry for Epidemiological Studies of Breast Cancer

NIH/NCI UO1 CA69417
Co-Investigator

1995-1999 Breast Cancer Education through Organized Labor

NIH/NCI RO1 CA66038
Co-Investigator

1997-2000 Prophylactic Surgery in Carriers of BRCA1 and BRCA2

NIH/NCI P30 CA16520
Co-Investigator

2000-2005 Dana-Farber/Harvard Cancer Center SPORE Grant in Breast Cancer
Core I: High Risk Patients and Their Families
NIH/NCI P50 CA089393
Co-Investigator

2001-2002 Prevalence of Germline TP53 Mutations in Young Women with Breast Cancer
Breast Cancer Research Foundation
PI

2001-2004 Breast Cancer Prevention in Hodgkin's Disease

NIH/NCI R21 CA87281
PI

2001-2004 Process and Outcomes of BRCA 1 / 2 Clinical Testing

NIH/NCI R21 CA87281
PI

2001-2006 Cancer Risk and Biomarkers of Tamoxifen Chemoprevention

NIH/NCI U10 CA37377
CO-Investigator

2002-2003 Can a Multivariable Model Using Tumor and Demographic Information Be Developed that will Identify BRCA1 Germline Mutation Carriers
Breast Cancer Research Foundation
PI

2002-2007 Project 6: Estrogen Receptor Negative Breast Cancer, Nuclear Receptor Ligands
DOD DAMD 17-02-1-0692
Co-PI

2003-2004 A Pilot Study of Pre-Operative Platinum Therapy: Can Tumor DNA – Repair Defects in the BRCA1 Pathway Predict a Response?
Breast Cancer Research Foundation
PI

2003-2003 A Randomized Study of the Effects of Tibolone on Bone Density, Menopausal Symptoms and Breast Density in High-Risk Women after Prophylactic Oophorectomy
DOD (DAMD 17-03-1-0708)
PI

2003-2008 Proteomic Analyses of Breast Nipple Fluid for Early Detection of Breast Cancer
DOD DAMD 17-03-10575
Co-Investigator
The project goal was to identify breast cancer-associated protein patterns in nipple fluids that may serve as biomarkers for the presence of neoplastic cells by collecting nipple fluid from 100 newly diagnosed breast cancer patients and 100 healthy patients who will serve as the comparison group.

2004-2005 Neoadjuvant Trial of GW572016

Breast Cancer Research Foundation/Baylor
Site PI

2004-2005 Prevalence of BRCA1 Germline Mutations among Women with "Triple Negative" Breast Cancer
Breast Cancer Research Foundation
PI
The project assessed the prevalence of BRCA1 germline mutations among women from the DF/HCC SPORE bank with ER/PR/HER2 negative breast cancer and the extent to which histology can improve estimates of the risk of carrying a BRCA1 mutation above that attributable to family history.

2004-2005 Biomarkers of Occult Ovarian Cancer from High-Risk Women Undergoing Prophylactic Oophorectomy
NIH/NCI (P50 CA105009)
Co-PI

2005-2006 Targeted Therapy for Basal-Like Breast Cancers: Development of Static and Functional Assays to Predict Response
The Breast Cancer Research Foundation
PI
The goal of this project was to continue to explore the basic hypothesis that sporadic basal-like human breast cancers (BLC) are phenotypically and molecularly similar to BRCA1-associated breast cancers and will respond similarly to therapies targeting BRCA1-associated tumor characteristics.

2005-2009 Multicenter Clinical Trials for TSC and Related Disorders

NIH/NCA/BWH R01 A107164
Co-Investigator (PI: Dabora)
The goal of this project was to study Rapamycin in patients with renal angioleiomyomatosis and tuberous sclerosis. (PI: Dabora)

2006-2007 Genetics of Familial Lobular Breast Cancer

The Breast Cancer Research Foundation
PI
The aim of this project was to examine the prevalence of germline CDH1 gene mutations invasive lobular breast cancer.

2006-2009 Predicting Response to Platinum in Triple Negative Breast Cancers: A DNA Damage Repair
NIH/NCI P30 CA006516-43S6
Co-PI

The goal of this project was to transform the characterization and treatment of basal-like tumors by determining the response of women with basal-like breast cancer to neo-adjuvant cisplatinum, which damages DNA in a specific way, the repair of which is compromised in BRCA1- associated tumors

2007-2008 Progesterone Receptor (PR) Expression in Normal Breast Tissue of BRCA1 Mutation Carriers: Preliminary Research for a Chemoprevention Trial
The Breast Cancer Research Foundation
PI ($208,000)
The goal of this study was to develop biomarkers for a larger study of anti-progestogens by 1) confirming or refuting the finding of the Progesterone Receptor dysregulation in BRCA1carriers and 2) if confirmed to interrogate a series of targets downstream of PR to develop biomarkers.

2004-2010 Telephone-Based Genetic Counseling: An Equivalence Trial

NIH/NCI/ R01 CA 108933
Site-PI (PI: M. Schwartz) ($150,900)
The goal is to conduct a telephone-based genetic equivalence trial by comparing the efficacy of genetic counseling delivered by telephone versus standard, clinic-based for women at risk for carrying a BRCA1/2 mutation

2005-2010 Dana-Farber Cancer Center/Harvard SPORE in Breast Cancer: Project 1: Biology and Treatment of BRCA1-Associated and Sporadic Basal-Like Cancers
NIH/NCI P50-CA89393
Co- PI (Co-PI: David Livingston) ($149,575)
The goal of this project seeks to find common molecular pathways shared by basal-like and BRCA1-linked cancers by conducting a preoperative clinical trial in HER2 and ER-negative cancers and analyzing trial specimens to identify tumor features predicting platinum response.

2005-2010 Dana-Farber Cancer Center/Harvard SPORE in Breast Cancer: Core 3 Cohort Studies and Databases
NIH/NCI P50-CA89393
Co-Investigator (PI: Dirk Iglehart and Jane Weeks) ($311, 463)
This project will identify patients at high risk of breast cancer who are likely to be informative in future cancer research.

2007-2010 Parent Communication of BRCA1/2 Test Results to Children

NIH/NHGRI R01 HG002686-05
Co-Investigator (PI: Kenneth Tercyak) ($43, 983)
The major goal is the continuation of the longitudinal study to examine decision making about disclosing a maternal BRCA 1 /2 test result to children

by (1) assessing the psychosocial outcomes of parent's communication choices among tested mothers and non-tested fathers.

2007-2012 Epidemiology of Syndromic GI Stomal Tumors (GIST)

NIH/NCI R01 CA125176 – 01A1
PI ($1,923,627)
The major goal of this project is to assemble a cohort of individuals with the abdominal sarcoma, GIST, and their relatives and, extending our previous findings, solicit clinical and family histories of pertinent neoplastic dermatologic and other conditions that may comprise previously unrecognized components of the syndrome.

2008-2010 The Role of BRCA1 in Breast Cell Differentiation and ALDH1+ Cells as Markers of Breast Cancer Risk in BRCA Mutation Carriers
The Breast Cancer Research Foundation
PI ($208,220)
The goal of this project is to determine whether the frequency of ALDH1 positive lobules in non-tumor breast tissue is related to the probability of BRCA1 tumorigenesis.

2008-2010 The Role of BRCA1 in Breast Cell Differentiation and ALDH1+ Cells as Markers of Breast Cancer Risk in BRCA Mutation Carriers
The Breast Cancer Research Foundation
PI ($208, 220)
The goal of this project is to determine whether the frequency of ALDH1 positive lobules in non-tumor breast tissue is related to the probability of BRCA1 tumorigenesis.

2008-2012 Development of Predictive Markers of Treatment Response in Basal-like Breast Cancer
The V Foundation for Cancer Research, Cary, NC
Co-PI (Co-PI: Daniel Silver) ($552,409)
The goal is to identify predictors of response to the DNA-targeting neo-adjuvant therapy of cisplatinum administered with bevacizumab, which targets VEGF by distinguishing women hose tumors will from those whose tumors will not be eliminated by agents targeting DNA repair

2009-2010 Comparison of Platinum-based v Anthracycline/Taxane-based Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Using Molecular Inversion Profiling (MIP)
Breast Cancer Research Foundation
PI ($166,666)
This project will investigate whether women who were sensitive to platinum salts would also be sensitive to more standard chemotherapeutic agents in

order to distinguish tumors by the type of agent to which they will respond before treatment.

2009-2014 Adolescents' Long-Term Adaptation to Familial Cancer Risks

NIH/NCI
Co-Investigator ($6,555)
This project looks at the long-term adaptation to familial cancer risks of adolescents between the ages of 12 – 21 whose mother, primary caretaker or legal guardian has participated in BRCA1/2 cancer genetic counseling and testing; who has elected to receive her test results between 1-5 years' prior to the proposed date of study enrollment, and who has disclosed her BRCA1/2 genetic results to her adolescent prior to the proposed date of study enrollment.

2010-2012 Characterization of BRCA2-Associated Breast Cancer

Breast Cancer Research Foundation
PI ($185,833)
The goal of this project is to be able to develop an easier way for pathologists to help find the subset of women with ER+/PR+breast cancers, who should be tested for BRCA1/2 mutations despite less family history, so that their therapy can be tailored to exploit their particular therapeutic vulnerability in DNA repair.

2010-2012 Pharmacogenetics of Platinum Response in Breast Cancer

Susan G. Komen for the Cure
PI ($50,000)
The project aims are to (1) utilize 2 complementary approaches to systematically evaluate the genetic differences between responders and nonresponders to cisplatin among women treated on 2 neoadjuvant trials for triple negative breast cancer (TNBC) and (2) to validate *snps* identified in aim 1 for prediction of response to cisplatin or carboplatin in a separate group of women receiving platinum agents for metastatic TNBC.

2010-2015 Preclinical and Brief Exposure Early Clinical Evaluation of an Oral PARP Inhibitor for Breast Cancer Prevention in BRCA Mutation Carriers
Susan G. Komen for the Cure
PI ($4,571,542)
The aims of this project are (1) to study three PARP inhibitors given orally, and compare them to see which can best reduce the development of tumors in mice engineered to have BRCA1 mutations in their mammary tissue, and to look for potential serious side effects; (2) to examine an oral PARP inhibitor that has been given to BRCA mutation carriers in breast and ovarian cancer treatment trials to examine its potential role in breast cancer prevention; (3) to

determine the lowest dose at which the agent's activity can be measured to arrive at the lowest effective dose going forward; (4) to look for the effects of the PARP inhibitor on important genes and proteins in breast tissue and breast stem cells; (5) to take identified biomarkers and adapt them for use with RPFNA, a technique that could be used to monitor women in a larger prevention trial to rapidly tell if the education is hitting the target in an individual.

2010-2014 Discover, Biology and Risk of Inherited Variants in Breast Cancer

NIH/NCI – U19CA148065
Co-PI ($13,179)
This multiple-PI Project aims to "systematically discover and replicate additional common genetic variants associated with breast cancer, assess their biological significance, and develop evidence based assessments of the clinical validity of prediction algorithms using these variants, and their suitability for translation into clinical practice."

2011-2018 Neoadjuvant Cisplatin Vs Doxorubicin/Cyclophosphamide ("AC") in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations
Breast Cancer Research Foundation
PI ($208,333)
The goal of this project is to better establish whether aggressive breast cancers in women with BRCA mutations are sensitive to platinum agents because of their specific deficiencies in DNA-repair or because the response to platinums is a surrogate for response to any cytotoxic chemotherapy. We will compare the responses of women with BRCA1/2 associated high-grade breast cancers (HER2-negative) receiving either cisplatinum or standard combination chemotherapy to compare the ability of these treatments to cause a "pathologic complete response," at the time of surgery, in the breast or lymph nodes.

2011-2012 Breast Cancers in Li Fraumeni Syndrome

DFCI Women's Cancer Program
PI ($180,000)
Li-Fraumeni Syndrome is characterized by an increased predisposition to diverse malignancies. Germline mutations in the tumor suppressor gene *TP53* are detectable in 70% of classic LFS families and breast cancer is the most common tumor among women with germline *TP53* mutations. The goals of this project are (1) to better able to recognize women with *TP53* mutations at diagnosis, which can be important for decisions about the use of therapeutic radiation in their management; (2) to learn something about the biology of these tumors, which can provide insight into other HER2 positive breast cancers(and ER+) and beyond to other tumor types that fall within the very wide spectrum of LFS, which includes nearly all pediatric and adult

neoplasms; (3) to study the tumors we have assembled from women with TP53 mutations in the hope of developing preventive strategies especially for those women with LFS who often develop breast cancer before the age of 25.

2012-2016 Combined CDK and PARP Inhibition in Triple Negative Breast Cancer

Susan G. Komen for the Cure
Co-PI (Co-PI: Geoffrey Shapiro) ($150,300)
Proposed specific aims: 1) Determine effects of reduced CDK1 and CDK2 activities on BRCA1 function and PARP inhibitor sensitivity in triple negative breast cancer cells; 2) Confirm synergistic effects of dinaciclib-mediated CDK inhibition on sensitivity of triple negative breast cancer cells to PARP inhibition *in vivo*; 3) Conduct a Phase 1 study of the CDK inhibitor dinaciclib (SCH727965) and the PARP inhibitor veliparib (ABT-888) without and with carboplatin in patients with advanced solid tumors

2012-2017 Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Reduction
NIH/NCI – RO1CA140245
Co-Investigator (PI: Smita Bhatia) ($30,745)
Using a Phase II randomized, double-blind, placebo-controlled trial of 5mg/day tamoxifen in childhoodand young adult cancer survivors treated with chest radiation, we aim to 1) determine the impact of a two0year course of low-dose tamoxifen on surrogate biomarkers of chemopreventive efficacy; 2) establish its safety and tolerability; and 3) examine the modifying effect of several well-defined demographic, clinical and molecular characteristics on the risk: benefit ration from intervention.

2012-2017 The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients

NIH - U01 HG006492 (Project 3)
Co-Leader (PI: Levi Garraway) ($1,500,000)
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients (Project 3)
The major goal of this project is to develop and implement a robust framework for the generation of genome sequencing data from “real-world” tumor materials, interpretation of the vast amounts of information that emerge, and the incorporation of relevant genomic information into the care of cancer patients and their families.

2012-2016 Stalled Fork Repair and Hereditary Breast Cancer Predisposition

Breast Cancer Research Foundation
PI ($208,300)
Aim 1: Determine the efficiency of different DNA damage repair responses in BRCA2 carrier (BRCA2+/-)-derived and wild type (BRCA2+/+) cells from

breast and skin tissue. Is SFR a BRCA2 dependent DNA damage repair function that is defective in heterozygous cells from BRCA2 mutation carriers? Aim2: Extend the stalled fork repair analysis to cells derived from ovarian tissue (ovarian surface epithelial cells or OSEs) and fallopian tube surface epithelial cells (FTEs) of BRCA1 mutation carriers. Are BRCA1+/- primary cells defective for repair of stalled replication forks? Aim3: Perform an exploratory study to determine whether a defect in stalled replication fork repair is one of the underlying defects in cells from women who carry a germline mutation in moderate risk breast cancer susceptibility genes (ATM, CHK2, PALB2, RAD51c) with roles in DNA repair.

2012-2019 VADIS Trial: Phase II trial of the E75 Peptide VAccine in Women with DCIS Breast Cancer
NIH/NCI Cancer Prevention Agent Development Program: Early Phase Clinical Research Consortium
Site PI
This is a mechanism for the conduct of early phase clinical trials of agents for prevention of diverse cancers. The current portfolio targets breast cancer with a trial of DHA, and a trial of a HER2-targeted vaccine trial has been approved and is in development for DCIS.

2012-2018 A randomized, double-blind, placebo-controlled study of 4-hydroxtamoxifen topic gel in women with mammographically dense breast - T011
NIH/NCI Cancer Prevention Agent Development Program: Early Phase Clinical Research Consortium
Site PI
This is a mechanism for the conduct of early phase clinical trials of agents for prevention of diverse cancers. The current portfolio targets breast cancer with a trial of DHA, and a trial of a HER2-targeted vaccine trial has been approved and is in development for DCIS.

2013-2014 Characterizing a new familial lung cancer syndrome through the identification and study of patients with germline *EGFR* T790M mutations
The Bonnie J. Addario Lung Cancer Foundation
Co-PI ($82,361)
The project aims: 1. To determine the prevalence of germline EGFR mutations in lung cancer patients with EGFR T790M mutations in their tumor and in eligible relatives of carriers of germline EGFR mutations. 2. To make a preliminary assessment of the natural history of lung cancers occurring in patients with germline EGFR mutations. 3. To generate an initial estimate of the prevalence of CT-detected lung nodules in individuals with germline EGFR mutations and no lung cancer diagnosis

2014-2017 Exploratory Study of Immune Cells in Breast Cancer

Susan G. Komen for the Cure

PI ($80,000)
To conduct an exploratory analysis, using immunohistochemistry, characterizing the immune populations of cells that can be targeted for immune therapies present in a. Triple negative breast cancers, b. ER positive/PR positive/HER2-negative cancers and to example the same immune cell populations in TNBC from women with germline BCRA1 mutations and ER+HER2-tumors from women with BCRA2 mutations to see whether there are differences from the "sporadic" group.

2017-2021 Evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ
NIH/NCI
Co-Investigator (PI: Kulkarni) ($17,927)
We propose to conduct a randomized placebo controlled window of opportunity trial with CE/BZA in 140 postmenopausal women with ER + DCIS.

2018-2020 Immunoprevention of BRCA1-associated breast cancer

HeritX
PI ($355,221)
The primary objectives of this award are (1) to demonstrate that the acquisition of TP53 missense mutations precedes progression to invasive breast cancer in BRCA1 mutation carriers; (2) to test whether these events induce p53-specific adaptive immune responses in BRCA1 carriers and (3) to identify any immunosuppressive conditions in the microenvironment that might facilitate immune escape.

<u>Current</u>

2013-2024 Dana-Farber/ Harvard SPORE in Breast Cancer
NIH/NCI- P50CA168504
Project Leader (PI: Eric Winer) ($1,345,196 Total SPORE)
The Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Breast Cancer seeks to improve the prevention and treatment of breast cancer through four integrated, innovative, and highly translational Projects which span all of the major breast cancer subtypes and range in scope from basic and preclinical science to epidemiologic and clinical studies. The overarching goal of the DF/HCC SPORE in Breast Cancer is to promote translational research that can lead to tangible clinical benefit.

2017-2021 Clonal Hematopoiesis (CHIP) and breast cancer
Breast Cancer Research Foundation (BCRF)
PI ($208,333)

Aim 1 To estimate the prevalence of clonal hematopoiesis of indeterminate significance (CHIP) at breast cancer diagnosis and to examine factors that may predict for its observation, including age, breast cancer subtype, treatment, and presence/absence of germline mutations in DNA repair genes (BRCA1/2, TP53, PALB2, Fanconi anemia genes). Aim 2 To compare the rate of CHIP after adjuvant chemotherapy to the rate among women following 6 months of adjuvant hormonal therapy without chemotherapy. Aim 3 To explore the effect of CHIP on breast cancer outcome, both treatment-related myeloid malignancy and time to recurrence.

2017-2022 Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers
NIH/NCI
Co-Investigator (PI: Timothy Rebbeck) ($2,408,257)
Optimize risk assessment by estimating individualized (precision) breast and ovarian cancer absolute risks by estimating precision cancer absolute risks by age, mutation and risk modifiers. Develop a web-based tool of precision absolute risks for use in clinical counseling.

2018-2022 Intercepting Pancreatic Cancer in High Risk Cohorts
SU2C Lustgarten Foundation
Co-Investigator (PI: Maitra) ($1,380,000)
The objectives are to produce end results that have relevant clinical impact for pancreatic cancer interception including the identification of high risk cohorts for pancreatic imaging, immune based interception via a vaccine trial, and biomarker studies to develop assays for use in cohorts with inherited cancer predisposition.

2018-2022 Development of Effective Hormonal Chemoprevention for BRCA2 Carriers
2017 BRCA 1,2 RESEARCH COLLABORATIVE GRANTS
PI ($545,455)
Specific Aim 1: Conduct a randomized phase II study in BRCA2 mutation carriers beginning 4-6 weeks following premenopausal RRSO (baseline), comparing a 3-month course of CE 0.45mg daily with the approved HRT combination: BZA 20mg plus CE 0.45mg daily (Duavee®). Specific Aim 2. To investigate the impact of CE, BZA and BZA/CE on ER signaling in normal mammary epithelial cells from BRCA2mutation carriers.

2019-2023 Prospectively Randomized, Placebo-Controlled Phase III Study to Determine the Effect of Denosumab on Breast Cancer Prevention
Department of Defense (DoD) Breast Cancer Breakthrough Award
PI ($3,972,511)

The primary objective of the BRCA-P phase III randomized placebo-controlled chemoprevention trial is to evaluate the reduction in risk of any BC (invasive or DCIS) in women with a gBRCA1m treated with DNSB compared to placebo.

2019-2024 Precision Approaches to Refining TP53-Associated Cancer Risk
NIH/NCI R01CA242218
Co-Investigator ($1,451,356)
The specific aims of this project are to, 1. Characterize TP53-related cancer risk and penetrance in a large collection of families with TP53 mutations, exploiting more agnostic multi-gene panel testing ascertainment strategies. 2. Evaluate molecular genetic modifiers of TP53-related penetrance across the full spectrum of ascertainments and phenotypes. 3. Determine the prevalence and clinical implications of ACE and TP53 mosaicism.

2019-2024 Statistical Methods and Tools for Cancer Risk Prediction in Families with Germline Mutations in TP53
NIH R01CA239342
Co-Investigator (PI: Wang) ($828,995)
The major goal of this project is to improve the clinical management of individuals with a family history of early-onset cancers by developing mathematical models to assess 1) germline mutation carrier probability prior to TP53 testing and 2) the absolute lifetime risk of developing cancers in individuals with TP53 mutations.

2019-2024 The AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes
NIH/NCI 1U01CA243688-01
Co-Investigator (PI: Mack) $2,401,850
The proposed study will develop and test a novel, patient- and family-centered model for cancer risk communication and decision-making to meet the unique needs of AYAs.

2019-2024 Development of Strategies to Track and Prevent Breast Cancer Development in BRCA Mutation
Basser Initiative
Co-Investigator (PI: Brugge) $129,465
It has been difficult to track and prevent breast cancer in BRCA1/2 mutation carriers because we do not yet understand how their cancers begin and progress. To address this challenge, we have assembled an internationally recognized team of basic and clinical scientists, who will build on exciting new findings that have identified the earliest changes in cells from ostensibly normal tissues from BRCA1/2-mutation carriers, to understand how they progress, and devise

clinically applicable approaches to track and suppress progression. The proposed work could transform both our understanding of breast carcinogenesis in BRCA1/2 mutation carriers, and our ability to predict and prevent

2020-2025 Count Me In: Partnering with Patients to Define the Clinical and Genomic Landscape of Rare Aggressive Sarcomas in Children and Adults
NIH/NCI 1U2CCA252974-01
Co-Investigator (PI: Wagle) $1,491,635)
The project is expected to engage patients directly and perform at least WES, RNA-seq, and low pass WGS in tumor samples (plus appropriate germline). The goal of the research is to generate a new knowledge from the genomic characterization. Return of actionable tumor and germline results from the WES is required but is not intended to be the focus of the research.

2021 - 2025 A Stakeholder Informed Randomized Trial of Pretest Video Education vs Standard Genetic Counseling for Cancer Patients: Evaluating the Impact on Patients, Providers and Practices
NIH/NHGRI 1R01HG011928
Co-Investigator (PI: Huma Rana)
The goal of this project is to compare behavioral and patient reported outcomes of pretest Video Education with Result Dependent Disclosure (VERDI) vs standard genetic counseling, to provide an evidence-based approach to modern cancer genetics care. We will evaluate the evolving role of genetic counselors as vital stakeholders in ensuring widespread implementation to expand access to genetics care, to optimize the delivery of genetic testing and counseling services to cancer patients who are otherwise undertested and underdiagnosed with cancer predisposition.

Projects Submitted for Funding

2022-2026
TRANS-END: A transformative program toward ending breast cancer through personalized risk assessment, tailored screening, and interception Breast Cancer Research Program, Transformative Breast Cancer Research Award
W81XWH-21-BCRP-TBCCA-2
Project PI: (PI: Powel Brown, MD Anderson) $24 million
The goal of this multi-disciplinary research consortium is to address three fundamental challenges: (1) how to best identify individuals who will develop breast cancer, (2) how to individualize breast cancer screening, and (3) how to prevent breast cancer in high-risk individuals.

Unfunded Current Projects

2021 Protocol 11-200 Whole body MRI surveillance for individuals at exceptionally high risk of cancer (Li Fraumeni Syndrome, SDH-syndromes, abnormal NIPT)

Report of Local Teaching and Training

Teaching of Students in Courses
Harvard School of Public Health

2000	Spring Workshop: Surrogate End Points 25-30 HSPH students and faculty	HSPH 2 hours
2001	Cancer Screening Course: Ethics and Implications of Genetic Testing for Cancer Susceptibility 25 students	HSPH 2 hours
2002	Ethics and Implications of Genetic Testing for Cancer Susceptibility 25 students	HSPH 2 hours
2003	Cancer Screening Course (Genetics): Ethics and Implications of Genetic Testing for Cancer Susceptibility 25 students	HSPH 1.5 hours
2004	Cancer Screening Course (Genetics): How Much Breast and Ovarian Cancer is Hereditary 30 students	HSPH 2 hours
2010	Cancer Prevention Course 30 students	HSPH 1 hour

Harvard Medical School

2002	Cancer Genetics: Molecular, Cellular and Tissue Radiation Biology Course: Breast and Ovarian Cancer Genetics 8 Radiation Oncology Fellows	HMS 1 hour
2002-07	Genetics Development and Reproductive Biology Course Tutor to 8-9 medical students (group session)	HMS 25.5 hours

2006-	Genetics and Reproductive Biology: Breast Cancer Genetics 150 first-year medical students	HMS 2 hours annually
2007	Medicine and Society: Breast/Ovarian Cancer Genetics 150 medical students	HMS 1.5 hours
2007	Role of Discovery in Medicine: Bench to Bedside: Breast Cancer Research 170 medical and dental students	HMS 1.5 hours
2010-	HMS Human Genetics Course: Human Genetics Clinic 150 Medical Students	HMS 2.5 hours

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2007	Human Trials and Genetics in Breast Cancer 10 medical subspecialty Fellows	Beth Israel Deaconess Medical Center, Boston, MA 2 hours
2011	Introduction to Cancer Genetics: 30 Genetics Residents	Harvard Medical School Boston, MA 45 min
2011-	Clinical Cancer Genetics 10 Radiation Oncology Residents	Dana-Farber Cancer Institute Boston, MA 1 hour
2015	Hereditary Breast and Ovarian Cancer Syndromes: Clinical Manifestations	Dana-Farber Cancer Institute Boston, MA 1 hour
2020	HMS High Impact Cancer Research	Harvard Medical School Boston, MA 1 hour

Clinical Supervisory and Training Responsibilities

1992-	Preceptor, DFCI Breast Oncology and High Risk Clinics	Supervision of a genetics or oncology fellow, primary care housestaff or medical student; 180 clinic sessions per year
1996 – 2010	Attending Physician, DFCI/BWH Cancer Center Inpatient Service / Attending Physician, Brigham and Women's Hospital	Supervision of 1 resident and 2 interns; 2 weeks per year
2005-	Faculty, Medical Oncology Fellows Case Report	7 medical oncology fellows, 2 hours per year
2005-	Faculty, Research Resident Research Report	4-6 BWH housestaff; 1.5 hours per year

Formally Supervised Trainees and Faculty

1995 – 1997 **Deborah Toppmeyer, MD /** Medical Director of the LIFE Center at the Cancer Institute of New Jersey at the University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School, Professor of Medicine, University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School, New Brunswick, NJ
Dr. Toppmeyer joined Dr. Garber and Dr. Donald Kufe as a post-doctoral fellow and studied breast cancer risk assessment and genetics with Dr. Garber, and pharmacology with Dr. Kufe.

1995 – 1998 **Deborah Schrag, MD, MPH /** Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Dr. Schrag worked with both Dr. Garber and Dr. Jane Weeks as a post-doctoral fellow studying the effectiveness of prophylactic surgery among carriers of breast and ovarian cancer and testing for inherited cancer susceptibility; published manuscript.

1998 – 2000 **Sapna Syngal, MD, MPH /** Senior Physician, Internal Medicine, Brigham and Women's Hospital, Boston, MA / Staff Physician, Dana-Farber Cancer Institute, Boston, MA / Director, Research Program in Genetics and Prevention of GI Malignancies, Brigham and Dana-Farber Cancer Institute / Director, Gastroenterology, Dan-Farber/Brigham and Women's Cancer Center; Director, Familial GI Cancer Program, Dana-Farber/Brigham and Women's Cancer Center, Professor of Medicine, Harvard Medical School, Boston, MA
Dr. Syngal joined Dr. Garber's group as a post-doctoral fellow and focused on focused on hereditary colorectal cancer: 11307K in CRC and adenomatous polyps and also the evaluation of MSH2 and MLH1 in HNPCC; received the 1999 and 2000 Dana-Farber Cancer Institute's Rising Star Award and the 1999 Dana-Farber Cancer Institute Marx Fellowship; published three manuscripts and many more as collaborators.

2000 – **Ann Partridge, MD, MPH /** Professor of Medicine, Harvard Medical School, Senior Physician, Vice Chair of Medical Oncology, Founder and Director, Program for Young Adults with Breast Cancer, Dana-Farber Cancer Center, Boston, MA
Dr. Partridge studied modulation of breast cancer risk by reduction of circulating estradiol levels using an aromatase inhibitor; published review.

2000 – 2001 **Susan Domchek, MD /** Basser Professor of Medicine, Executive Director, Bassett Center for BRCA Research, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Dr. Domchek studied biomarker development in breast duct lavage fluid; published manuscript.

2001 – 2002 **Peter Ang, MD /**, Consultant Medical Oncology, Oncocare Cancer Centre, Singapore, China / Assistant Professor, National Cancer Center, Singapore, China
Dr. Ang studied BRCA 1 and BRCA 2 related breast cancers and with Dr. Garber published review.

2002 – 2004 **Judith Balmana, MD PhD /** Head, Hereditary Cancer Genetics Group, Department of Medical Oncology/ Professor of Medicine, University Hospital Vall d'Hebron, Barcelona, Spain
Dr. Balmana, came to DFCI as a post-doctoral fellow and worked with both Drs. Garber and Sapna Syngal investigating the motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes and studied sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles; published manuscript.

2004 – **Serena Masciari, MD /** Associate Director, Global Safety in Oncology, Genzyme, Boston, MA
Dr. Masciari joined Dr. Garber's group as a post-doctoral fellow and initiated a multi-faceted research approach to Li Fraumeni Syndrome which included formulating two clinical studies; in 2006 awarded a Charles King Postdoctoral Fellowship and a Patterson Fellowship; has also studied F18 fluorodeoxyglucose positron emission tomography/computed tomography screening in Li-Fraumeni Syndrome and hereditary diffuse gastric cancer and its associations with lobular breast cancer; is currently supported by Drs. Garber and Sapna Syngal and working on her Masters in Science in Epidemiology from the Harvard School of Public Health through the Harvard Medical School training program, Scholars in Clinical Science; studying gastrointestinal tumors and Li Fraumeni syndrome as well as characteristics of breast cancer and Li Fraumeni Syndrome; published two manuscripts and has 2 in preparation.

2005 – 2006 **Nina Larsson, MD, PhD** / Director, Clinical Genetics, Lund University Hospital, Lund, Sweden
During her training with Dr. Garber, Dr. Larsson collaborated on the lobular breast cancer project and co-authored the study paper.

2005-2006 **Michaela Kandel, MD** / Physician (OB/GYN), University Hospital of Schleswig-Holstein, Kiel Germany
Dr. Kandel joined Dr. Garber's group as a post-doctoral fellow and focused on projects looking at basal cytokeratin and epidermal growth factor receptor expression in women with triple-negative breast cancers and Germline-E cadherin mutations in familiar lobular breast cancer; is a co-author on study paper.

2006-2008 **Zsofia Stadler, MD** / Clinical Director, Cancer Genetics Service, Associate Professor in GI Oncology and Cancer Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY
Dr. Kandel joined Dr. Garber's group as a post-doctoral fellow and during that time worked on the Dr. Garber's 2007 Breast Cancer Research Foundation project, the study of progesterone receptors in BRCA 1 breast tissue; drafted the document that became the grant application, which was funded, and subsequently prepared and submitted the study protocol to the IRB; published a manuscript.

2007 -2009 **Brian Alexander, MD** MPH/ Chief Executive Officer, Foundation Medicine
Dr. Garber supervised Dr. Alexander's participation on a project entitled "DNA repair protein biomarkers associated with time to recurrence in triple negative breast cancer;" co-author on study paper, manuscript in preparation.

2009-2011 **Verena Engelstaedter, MD** / OB/GYN Resident in Obstetrics and Gynecology, Ludwig-Maximilians-University, Munich, Germany
As Dr. Garber's trainee, Dr. Engelstaedter, worked with PI Joyce Liu on a sponsored project investigating BRCA 1 / 2 genotype and platinum resistance in ovarian cancer.

2010 – 2012 **Georgios Lypas, MD** / Oncologist, Hygiea Hospital, Athens Greece
Under Dr. Garber's supervision, Dr. Lypas is working on a project entitled "Tailoring chemotherapy for early stage triple-negative breast cancer or BRCA-1 or 2 related cancers."

2010 - 2014 **Michelle Rath, MD** / J. Heil Department of Gynecology and Obstetrics, University Hospital, Heidelberg, Germany
Dr. Garber supervised Dr. Rath's study of the prevalence of germline TP53 mutations in women with HER2+ breast cancers

2012 - 2015 **Yun Song, BS /** Surgical Resident, University of Pennsylvania, Philadelphia PA
Dr. Garber supervised Ms. Song's project titled "Clinical outcomes and relapse patterns in BRCA1/2 mutation associated and non-BRCA associated early breast cancers." The manuscript was published while she was a surgical resident.

2012- **Junne Kamihara, MD PhD**/ Instructor in Pediatrics, Dana-Farber Cancer Institute
Dr. Kamihara is now leading the Pediatric Cancer Genetics clinical program at DFCI.

2013 - 2014	**Eunkyung Park** /Associate Professor, Department of Obstetrics and Gynecology, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Korea Dr. Garber supervised Dr. Park's project titled "Germline panel testing in a sequential series of breast cancer patients"
2014 - 2015	**Luca Livraghi, MD** / Medical Oncologist, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy Dr. Garber supervised Dr. Livraghi's projects entitled "Exploratory Study of Immune Cells in Triple Negative Breast Cancer" and "Prevalence of germline mutations in women with high grade ER+ breast cancer".
2014-2015	**Signe Borgquist, MD, PhD** Chair Professor of Oncology, Aarhus University, Denmark Dr. Garber and Dr. Borgquist collaborated on several projects exploring the role of statins in breast cancer risk and outcomes.
2018-2021	**Israel Gomy, MD** /Assistant Professor, Faculdades Pequeno Principe, Curitiba, Brazil Dr. Garber supervised Dr. Gomy's work on the application of bioinoformatic approaches to somatic and germline data from the Dana-Farber Profile dataset. The work was performed in collaboration with investigators at Rutgers and published in JCO-Precision Oncology after presentation at AACR 2020

Formal Teaching of Peers (CME)

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

1999-2001	Genetics of Inherited Cancer Syndromes HMS Cancer Medicine and Hematology	One lecture per year Boston, MA
1999-	Women at High Risk for Breast Cancer HMS Advances in Cancer Management for the Surgeon	One lecture per year Boston, MA
2001-	Breast Cancer Updates HMS Current Concepts in Chemoprevention	One lecture per year Boston, MA
2001	Breast Cancer Risk Factors and Prevention Strategies HMS/DFCI Breast Pathology: Current Controversies and New Horizons	One lecture per year Boston, MA
2002-	High Risk Familial Cancer Syndromes HMS Cancer Medicine and Hematology	One lecture per year Boston, MA

2002	Role of Prophylactic Mastectomy and Oophorectomy for Prevention in High-Risk Patients HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA
2003	Clinical Management of BRCA1/2 Mutation Carriers HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA
2004	Reducing Breast Cancer Risk in Carriers and Non-Carriers HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Current Controversies and New Horizons	One lecture per year Boston, MA
2005	How to Manage the High-Risk Patient in Breast Cancer HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Current Controversies and New Horizons	Single presentation Boston, MA
2006	Triple Negative Breast Cancer HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Current Controversies and New Horizons	One lecture per year Boston, MA
2006-	Genetics of Breast and Ovarian Cancer HMS/Children's Genetic Basis of Adult Disease: What the Primary Care Provider Needs to Know	One lecture per year Boston, MA
2007-	Heritable Breast and Ovarian Cancer HMS Pediatric and Adolescent Gynecology Course	One lecture per year Boston, MA
2008	Impact of Genetics on Breast Oncology Practice HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA

2008	Update on Breast Cancer Genetics DFCI–Emerging Strategies in Breast Cancer: Targeting Tomorrow's Therapies Today	Single presentation Boston, MA
2008	Breast Cancer/Genetics Epidemiology Pri-Med / Dana-Farber Cancer Institute Oncology Masterclass (Pri-Med)	One to four lectures per year Los Angeles, CA
2009	Triple Negative Breast Cancer: Problems and Possibilities HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA
2009	Genetic Testing in Breast Cancer – Appropriate Patient Selection and Implications for Management Pri-Med / Dana-Farber Cancer Institute Oncology Masterclass (Pri-Med)	One to four lectures per year Washington, DC, San Francisco, CA, Miami, FL
2010	Preoperative Therapy for Triple Negative Disease HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA
2010	Breast Cancer and Genetics: A Practical Guide to Identifying and Managing High-Risk Patients Dana-Farber Cancer Institute Oncology Masterclass (PMI-CME)	One to four lectures per year Pasadena, CA Washington, DC, Dallas, TX
2011	Reporting Research Results DFCI OHRP Conference: Protecting Human Subjects in Research: Blending Regulatory Requirements and Best Practices	Single Presentation Boston, MA
2011	PARP Inhibitors and Their Potential Roles in Treating Hereditary Breast Cancer Dana-Farber Cancer Institute Oncology Masterclass (PMI-CME)	One to four lectures per year Washington, DC, Miami, FL

2011	Breast Cancer Prevention HSPH Cancer Prevention Class	Single lecture Boston, MA
2012	Breast Cancer and Genetics: A Practical Guide to Identifying and Managing High-Risk Patients Dana-Farber Cancer Institute Oncology Master Class (Knowledge to Practice)	One to four lectures per year Washington, DC Los Angeles, CA
2013	High Risk Breast Cancer: Diagnosis and Management of Patients with Hereditary Cancers Dana-Farber Cancer Institute Oncology Master Class (Knowledge to Practice)	One to four lectures per year San Francisco, CA
2014	Breast Cancer Genetics: Recent Advances and Current Management for High Risk Patients Dana-Farber Cancer Institute Oncology Master Class (Knowledge to Practice)	One to four lectures per year Chicago, IL San Francisco, CA
2015	Hereditary Breast Cancer: Testing for Syndromes Beyond BRCA 1/2 Disease HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA
2016	Screening Populations for Hereditary Cancer HMS/DFCI/BWH Cancer Center and MGH Cancer Center – Breast Cancer: Current Controversies and New Horizons	One lecture per year Boston, MA
2017-	Hereditary Breast Cancer: Beyond BRCA ½ Schlager Lecture Breast Cancer: New Horizons, Current Controversies Course	One lecture Boston, MA
2017	Breast Cancer Genetics Oncoclinicas Educational Course	One lecture Boston, MA

Local Invited Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

1998	Genetics of Breast Cancer Susceptibility / Oncology Grand Rounds

Dana-Farber/Partners Cancer Care, Boston, MA

1998 Hereditary Breast Cancer / Pathology Grand Rounds
Beth Israel Deaconess Medical Center, Boston, MA

1998 Genetic Screening in Cancer / Medical Grand Rounds
Boston VA Medical Center, Boston, MA

1998 Inherited Breast Cancer: Risk Assessment and Management / Medical Grand Rounds
Faulkner Hospital, Boston, MA

1998 Clinical Crossroads: Breast Cancer Genetics / Hematology-Oncology Grand Rounds
Beth Israel Deaconess Medical Center

1998 Breast Cancer Prevention / OB/GYN Grand Rounds
Massachusetts General Hospital, Boston, MA

1998 Chemoprevention of Breast Cancer / OB-GYN Grand Rounds
Massachusetts General Hospital

2000 Genetic Cancer Screening / Oncology Grand Rounds
Boston VA Medical Center

2000 Hormone Replacement Therapy: Where Are We Now? / Medical Grand Rounds
Brigham and Women's Hospital, Boston, MA

2000 Reducing the Incidence of Breast Cancer Through Genetics / Medical Grand Rounds
North Shore Medical Center, Danvers, MA

2000 Issues in Clinical Cancer Genetics / Genetics Seminar Series
Children's Hospital, Boston, MA

2000 Women's Health in the Post-Genomic Age / Invited Speaker
Harvard Center for Women's Health, Boston, MA

2000 Hereditary Risk of Breast and Ovarian Cancer: Answering your Patient's Questions / Medical Grand Rounds
Newton-Wellesley Hospital, Newton, MA

2002 Breast Cancer Risk Factors and Prevention Strategies / Pathology Grand Rounds
Beth Israel Deaconess Medical Center

2002	Breast Cancer Prevention Study / Medical Grand Rounds Brigham and Women's Hospital
2002	Recognizing and Managing Women with Hereditary Breast/Ovarian Cancer Risk / Medical Grand Rounds Faulkner Hospital
2002	Breast Cancer Screening and Early Diagnosis / Grand Rounds Harvard University Health Services, Boston, MA
2002	Breast Cancer Risk and Prevention / Medical Grand Rounds West Roxbury VA Medical Center, West Roxbury, MA
2003	Breast Cancer Genetics and Prevention / Medical Grand Rounds Cambridge Hospital, Cambridge, MA
2003	Aromatase Inhibitors in Breast Cancer Prevention / Hematology-Oncology Grand Rounds Dana-Farber Cancer Institute
2004	BRCA-1-Associated Cancer: One Young Woman's Experience / Breast Cancer Conference Dana-Farber Cancer Institute
2004	Team Approach to Managing Hereditary Breast Cancer / Conference on Women and Cancer Brigham and Women's Hospital
2005	BRCA 1 / 2 Associated Cancers / Women's Cancer Center Visiting Committee Dana-Farber Cancer Institute
2005	Genetics of Lobular Breast Cancer / Tumor Board North Shore Medical Center
2006	Pre-Operative Platinum Trials / Basal Breast Cancer Meeting Harvard Medical School
2006	Breast Cancer Screening / Medical Grand Rounds Faulkner Hospital
2006	Genetics of Lobular Breast Cancer / Women's Cancers Program Clinical Translational Retreat Dana-Farber Cancer Institute

2006	Identification and Management of Women at High Risk for Breast and Ovarian Cancers / Medical Grand Rounds Brigham and Women's Hospital
2008	Genetics of Lobular Breast Cancer / Women's Cancers Program Clinical Translational Retreat Dana-Farber Cancer Institute
2009	Evolution of Clinical Breast Cancer Genetics / OB/GYN Grand Rounds Massachusetts General Hospital
2010	Evolution of Clinical Cancer Genetics / Medical Grand Rounds Beth Israel Deaconess Hospital
2010	Breast Cancer Genetics for the Oncologist / Multidisciplinary Breast Rounds Massachusetts General Hospital
2010	Breast Cancer Genetics for the Oncologist / Multidisciplinary Breast Rounds Massachusetts General Hospital
2011	Update on Breast Cancer Genetics and How Genetics Is Informing Diagnosis and Treatment / Medical Grand Rounds Faulkner Hospital
2012	Evolution of Breast Cancer Genetics Obstetrics and Gynecology Grand Rounds Brigham and Women's Hospital
2013	Assessing Breast Cancer Risk and Opportunities for Breast Cancer Prevention Cancer Medicine and Hematology Dana-Farber Cancer Institute
2014	Cancer Genetics for the Primary Care Practitioner / CME Conference MIT Medical, Cambridge, MA
2014	BRCA/Breast Cancer / CME Conference MIT Medical, Cambridge, MA
2014	Assessing Breast Cancer Risk and Opportunities for Breast Cancer Prevention Cancer Medicine and Hematology Dana-Farber Cancer Institute

2015	Breast Cancer Genetics: What Surgeons Need to Know Surgical Grand Rounds Mount Auburn Hospital, Cambridge MA
2015	Genetics in Gynecologic Oncology Gyn Onc Lecture Series Brigham and Women's Hospital, Boston, MA
2015	Intro to Cancer Genetics New Genetics Fellow Orientation Lecture Brigham and Women's Hospital, Boston, MA
2016	Intro to Cancer Genetics New Genetics Fellow Orientation Lecture Brigham and Women's Hospital, Boston, MA
2016	Passing it on: The Genetics of Cancer Women & Cancer Conference Dana-Farber Cancer Institute, Boston, MA
2017	TP53 mosaicism: a special case of CHiP Genomic Case Conference Massachusetts General Hospital, Boston, MA
2017	Breast Cancer: Risk, Genetics and Prevention Cancer Medicine and Hematology Dana-Farber Cancer Institute
2018	Evolution of Breast Cancer Genetics Obstetrics and Gynecology Grand Rounds Brigham and Women's Hospital

Report of Regional, National and International Invited Presentations and Courses

Regional

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

1997	Clinical Aspects of Genetic Testing for Cancer / Medical Grand Rounds North Shore Medical Center, Salem, MA
1997	Genetic Testing and Cancer / Program for Practicing Physicians Whitehead Institute, Cambridge, MA
1997	Practical Issues in Genetic Testing for Cancer Susceptibility / Medical Grand Rounds

Boston University Medical Center, Boston, MA

1997 Genetics of Breast Cancer / Medical Grand Rounds
St. Elizabeth's Hospital, Boston, MA

1997 Cancer Genetics / Issues in Genetics Conference
Massachusetts Institute of Technology, Cambridge, MA

1997 Breast Cancer Genetics / Research Milestones Series
Dartmouth Medical Center, Hanover, NH

1997 Practical Issues in Genetic Testing for Cancer Susceptibility / 9th Annual Symposium
New England Area Cancer Research, Providence, RI

1997 Clinical Issues in Breast Cancer Susceptibility / Medical Grand Rounds
Yale Cancer Center, New Haven, CT

1998 Inherited Predisposition to Cancer: Implications for Medical Practice
American College of Physicians, Boston, MA

1998 Cancer Genetics / Medical Grand Rounds
Maine Center for Cancer Medicine, Portland, ME

1998 Breast Cancer Genetics: Issues and Challenges / Oncology Grand Rounds
Women and Infants Hospital, Providence, RI

1998 Genetic Testing in Breast Cancer and Colon Cancer – The Implications / Hematology-Oncology Symposium
Saint Francis Hospital and Medical Center, Hartford, CT

1998 Assessing and Managing Hereditary Risk of Breast Cancer / Medical Grand Rounds
Boston University Medical Center, Boston, MA

1998 Issues in Breast Cancer Risk Assessment and Management / Medical Grand Rounds
Winchester Hospital, Winchester, MA

1998 Genetic Issues in Breast Cancer / Medical Grand Rounds
Worcester Memorial Hospital, Worcester, MA

1999 Issues in Breast Cancer Genetics / Surgical Grand Rounds
St. Elizabeth's Medical Center, Boston, MA

1999	Genetic Testing for Breast and Colon Cancer / Medical Grand Rounds Saint Vincent Hospital, Worcester, MA
1999	Breast Cancer Risk Assessment and Management / Medical Grand Rounds Deaconess-Glover Hospital, Needham, MA
2000	Cancer Genetics / Medical Grand Rounds Saint Anne's Hospital, Fall River, MA
2003	Current Strategies in Breast Cancer Prevention / Surgical Grand Rounds St. Elizabeth's Medical Center
2003	Breast Cancer Risk and Prevention / Medical Grand Rounds Eastern Maine Medical Center, Bangor, ME
2004	Breast and Ovarian Cancer Risk / Conference Eastern Connecticut Health Net Hospital, Hartford, CT
2004	Does it Run in the Family? The Link Between Breast Cancer and Genetics / John A. DeQuattro Memorial Lecture Eastern Connecticut Hospital, Manchester, CT
2004	Practical Issues in the Management of Hereditary Breast and Ovarian Cancer Risk / Medical Grand Rounds Caritas Hospital, Norwood, MA
2004	Clinical Cancer Genetics / Medical Grand Rounds Metrowest Medical Center, Worcester, MA
2005	Breast and Ovarian Cancer Genetics / Spring Symposium Hudner Oncology Center, North Dartmouth, MA
2005	Risk Factors: New Developments and Current Research / Program on New Directions in Breast Cancer Care Elliot Hospital & Catholic Medical Center, Bedford, NH
2005	Familial Cancer Genetic Syndromes / Medical Grand Rounds Exeter Hospital, Exeter, NH
2005	Breast and Ovarian Cancer Genetics / Annual Spring Cancer Symposium Hudner Oncology Center, North Dartmouth, MA
2006	Assessment and Medical Management of Women at High Risk for Breast Cancer / Lee Ann Riley Memorial Breast Symposium

Bridgeport Hospital, Bridgeport, CT

2005 The Role of Genetic Analysis in Assessing Breast Cancer Risk / American Society of Breast Cancer Disease Program: Challenges in Contemporary Breast Cancer Diagnosis and Management
American Society of Breast Disease, Ledyard, CT

2006 The Role of Genetic Analysis in Assessing Breast Cancer Risk / Annual Meeting
American Society of Breast Disease / Rhode Island Hospital, Providence, RI

2006 Risk Reduction Strategies for BRCA 1 / 2 Mutation Carriers / Region I Education Conference
National Society of Genetic Counselors, Marlborough, MA

2006 Management of BRCA 1 / 2 Mutation Carriers / Genetics Grand Rounds
Tufts-NEMC Medical Center, Boston, MA

2006 Genetic Testing for Cancer Risk / Medical Grand Rounds
Lowell General Hospital, Lowell, MA

2007 Breast Cancer Screening / Medical Grand Rounds
Cambridge Hospital, Cambridge, MA

2007 Identifying and Managing Hereditary Cancers / Medical Grand Rounds
Concord Hospital, Concord, NH

2008 Heritable Breast and Ovarian Cancer / Annual Meeting and Education Session
American College of Obstetricians and Gynecologists (Massachusetts section), Waltham, MA

2009 Using a Cancer Genetics Counselor / Medical Grand Rounds
Exeter Hospital, Exeter, NH

2010 Assessing and Managing Breast Cancer Risk / Grand Rounds
Lahey Clinic, Burlington, MA

2016 Medical Management of BRCA Mutation Carriers
Society of Surgical Oncology Annual Meeting, Boston, MA

2016 Incorporating Genetics into Clinical Practice in Breast/GYN Oncology
Update on Breast and Gynecologic Cancers Meeting
Dana-Farber Cancer Institute, Boston, MA

2016	Genetic Predispositions to Breast and Ovarian Cancer Cancer Biology and Therapeutics Program Recorded Online Lecture Harvard Medical School, Boston, MA
2017	Prevention of invasive breast cancer: new opportunities DF/HCC DCIS Retreat Harvard Medical School, Boston, MA
2018	DNA in the Blood: Inherited Mutations, CHIP, and Cell-free DNA Dana-Farber Cancer Institute, Boston, MA
2019	PROACTIVE: Broad-based germline DNA testing DFCI Trustees Committee Presentation Dana-Farber Cancer Institute, Boston, MA

National

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

1997	Genetics of Inherited Cancers / Annual Meeting American Society of Therapeutic Radiation Oncology, Los Angeles, CA
1997	Issues in Genetic Testing for Cancer Susceptibility / Multidisciplinary Clinical Conference Series Johns Hopkins Oncology Center, Baltimore, MD
1997	Clinical Cancer Genetics of Breast Cancer / Special Conference American Association for Cancer Research, Keystone, CO
1997	Hallmarks of Inherited Cancer: Research Opportunities for Clinicians / Berlex Oncology Foundation, San Diego, CA (Berlex)
1997	Update and Perspectives on Psychosocial Aspects and Human Subject Concerns in Genetic Testing in Research / Annual Meeting 20th Annual Meeting of American Society of Preventive Oncology, New Orleans, LA
1997	The Genetics of Breast Cancer / Medical Grand Rounds Greater Baltimore Medical Center, Baltimore, MD
1997	What is the Role of Prophylactic Surgery in Breast and Ovarian Cancer? Annual Meeting American Association for Cancer Research, San Diego, CA

1997 Ethical Issues and Clinical Counseling of High-Risk Women / Biennial Meeting
Helene Harris Memorial Trust, Los Angeles, CA

1997 Familial Breast Cancer / Annual Meeting
American Society of Clinical Oncology, Denver, CO

1997 Breast Ovarian Cancer Predisposition Syndromes / Course on Cancer Genetic Counseling and Testing (CME Course)
Memorial Sloan-Kettering Cancer Center and Sarah Lawrence College, NY

1997 Approaches to the Study of Highly Predictive Genetic Markers – Experiences with BRCA 1 / 2 / Annual Meeting
American College of Epidemiology, Atlanta, GA

1997 BRCA1 and Other Genetic Risk Profiles: Bane or Benefit / Annual Conference
American College of Surgeons, Chicago, IL

1997 Directions in Breast Cancer Genetics Research / Medical Grand Rounds
University of Texas Southwestern Medical School, Dallas, TX

1997 Clinical Applications of Breast Cancer Genetics / Conference
National Conference on Genetics in Managed Care, Washington, DC

1998 Testing for Inherited Cancer Susceptibility / Annual Meeting
American Association of Clinical Chemists, Boston, MA

1998 Genetics of Breast Cancer / Annual Meeting
American College of Surgeons, Orlando, FL

1998 Genetics of Familial Neoplasia / Annual Research Day
University of South Florida, Tampa, FL

1998 Hereditary Breast Cancer / Annual Meeting
Northern California Oncologists, San Francisco, CA

1998 Colorectal Cancer Screening and Prevention / Annual Meeting
American College of Physicians, San Diego, CA

1998 Breast Cancer Genetics / Satellite Symposium on Cancer Genetics
American Society of Clinical Oncology, Los Angeles, CA

1998 Genetics of Breast and Ovarian Cancer / Symposium

New Jersey State Cancer Symposium, Princeton, NJ

1998 Breast/Ovarian Cancer Genetics / Symposium
City of Hope National Medical Center Symposium, Duarte, CA

1998 Breast Cancer Genetics: Implications for Medical Practice / Medical Grand Rounds
Mary Imogene Bassett Hospital, Cooperstown, NY

1999 Genetic Screening for Cancer: Lessons from the Breast Cancer Experience / Annual Symposium
St. Jude Children's Research Hospital, Memphis, TN

1999 Hereditary Cancer Syndromes: Translating Research into Practice / Oncology Seminar
University of Michigan, Ann Arbor, MI

2000 Update on Management of Women with Hereditary Breast and Ovarian Cancer Risk / CME Course
University of Chicago, Chicago, IL

2001 Breast Cancer Risk Factors / Symposium
Susan B. Komen Foundation, Dallas, TX

2001 Ethical Challenges in Predisposition Testing: The Example of Hereditary Breast and Ovarian Cancer Susceptibility / Annual Scientific Conference
Food and Drug Administration, Washington, DC

2001 Breast and Ovarian Cancer Genetics: Implications for Care / OB/GYN Grand Rounds
Greater Baltimore Medical Center, Baltimore, MD

2001 Chemoprevention of Inherited Ovarian Cancer
Helene Harris Memorial Conference on Ovarian Cancer, Houston, TX

2002 Genes, Breast Cancer and Ethics / Annual Meeting
American Association for the Advancement of Science, Boston, MA

2002 Hereditary Breast and Ovarian Cancer / Oncology Grand Rounds
Vanderbilt University School of Medicine, Nashville, TN

2002 Breast Cancer Genetics and Prevention / Medical Grand Rounds
Saint Vincent's Hospital and Medical Center, New York, NY

2002 Genetic Testing / Annual Meeting

American Association for Cancer Research, San Francisco, CA

2002 Multidisciplinary Approach to Treating Breast Cancer / Annual Meeting
American Society of Clinical Oncology, Orlando, FL

2002 Cancer Prevention and Control / Research Conference
National Institutes of Health, Rockville, MD

2002 Genetics in Medicine / Annual Meeting
The Endocrine Society, San Francisco, CA

2002 Identification and Management of Women with Hereditary Breast and Ovarian Cancer Risk
Inova Institute of Research and Education, Falls Church, VA

2003 Hereditary Breast Cancer / Medical Grand Rounds
Henry Ford Health Systems, Detroit, MI

2003 Clinical Issues in Breast Cancer: Risk Assessment and Reduction / Medical Grand Rounds
Mount Zion Hospital, San Francisco, CA

2003 Prevention of Breast and Ovarian Cancer / Conference
Network for Medical Communication and Research (NMCR), Women's Issues in Oncology Meeting, Scottsdale, AZ (NMCR)

2003 Quantitative Risk Assessment and Atypia Among Women with Genetic Predisposition / Evaluation of Ductal Lavage Research Meeting
National Cancer Institute, Bethesda, MD

2003 Hereditary Breast Cancer / Advances in Breast Cancer Research Conference
American Association for Cancer Research, Huntington Beach, CA

2003 Risk Assessment, Screening, and Management of BRCA 1 / 2 Mutation Carriers: Cancer Prevention Among Women at Increased Risk / Annual Meeting
American Society of Clinical Oncology, Chicago, IL

2003 Identifying and Managing Genetic Risk: BRCA 1 / 2
Annual Adjuvant Therapy in Breast Cancer Congress, New York, NY

2003 Breast Cancer Genes and Other Factors / Management of High Risk Breast Cancer Patients / Symposium
Annual Multidisciplinary Symposium, Amelia Island, FL

2004 Breakout Risk Prediction Models for Genetic Susceptibility / Workshop

NIH/NCI Cancer Risk and Prediction Models: A Workshop on Development, Evaluation and Application, Washington, DC

2004 Breast Cancer Genes: Beyond BRCA1/2 / Annual Meeting
American Society of Clinical Oncology, New Orleans, LA

2004 How Much Breast and Ovarian Cancer is Hereditary? / Roche Lecture
Robert Wood Johnson Medical School – Cancer Institute of NJ, New Brunswick, NJ

2004 Hereditary Breast Cancer Genetics / Cancer Course
American Association for Cancer Research, Aspen, CO

2004 Use of Random Periareolar Fine Needle Aspiration for Acquisition of Breast Epithelial Cells and Comparison to Ductal Lavage
EDRN Breast/GYN Collaborative Group Workshop: Progress toward Early Detection Biomarkers, New York, NY

2005 Prophylactic Surgery for Women at High Risk of Breast and Ovarian Cancer / Annual Meeting
Scripps Cancer Center, La Jolla, CA

2005 (1) Breast Cancer Risk Assessment, Genetics and Prevention
(2) Genetic Testing for Cancer / Annual Meeting
American College of Physicians, San Francisco, CA

2005 Preventing and Treating BRCA 1 / 2 – Related Breast Cancer / Course
Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy
New York, NY

2005 Translational Research: Novel Approaches / Special Conference on Advances in Breast Cancer Research
American Association for Cancer Research, La Jolla, CA

2005 Prophylactic Surgery for Women at High Risk of Breast and Ovarian Cancers / Annual Conference
6th Annual Hampton Roads Oncology Education Conference, Virginia Beach, VA

2005 Managing Menopause after Breast Cancer / Annual Symposium
San Antonio Breast Cancer Symposium, San Antonio, TX

2005 Can Breast Cancer Be Prevented in High Risk Women? CME Course
University of Chicago Conference: Cancer Control Through Genetics: An Advanced Practical Approach, Chicago, IL

2006	(1) Genetic Testing: Then and Now / Annual Meeting (2) Hereditary Cancer: Genomics Comes of Age 17th Annual National Interdisciplinary Breast Center Conference, Las Vegas, NV
2007	Principles of Cancer Genetics / Annual Meeting National Consortium of Breast Centers, Las Vegas, NV
2007	Preoperative Treatment of Triple-Negative (basal phenotype) Breast Cancer / Meeting on Preoperative Therapy in Invasive Breast Cancer Reviewing the State of the Science and Exploring New Research Directions / NIH Meeting National Cancer Institute, Bethesda, MD
2007	Triple Negative Breast Cancer / Annual Conference Annual Biological Basis of Breast Cancer Conference, Santa Monica, CA
2007	Panel on Basal-like Breast Cancer: Designing Rational Treatments / Annual Meeting American Association for Cancer Research, Los Angeles, CA
2007	(1) Hereditary Diffuse Gastric Cancer (2) SNP Analysis: Where will they inform oncology? / Annual Meeting American Society of Clinical Oncology, Chicago, IL
2007	Implementation Strategies in Response to Risk / Conference The Governor's Conference on Effective Partnering in Cancer Research, Princeton, NJ
2007	Understanding and Treating Basal Breast Cancer / Annual Congress 6th Annual Congress on the Future of Breast Cancer, Kohala Coast, HI (PER – Physicians' Education Resource)
2007	Biomarkers of Risk and Response in Prevention Trials / NIH Meeting NIH Stratified Cancer Prevention Meeting, Bethesda, MD
2007	Exploiting DNA Repair Defects in Breast Cancer Treatment / Conference AACR Special Conference on Breast Cancer, San Diego, CA
2007	Familial Cancer Syndromes / Hematology / Oncology Board Review Course George Washington University Medical Center, Washington, DC
2007	Genetic Screening for Breast Cancer: Who should be Screened? CME Program Great Debates in Breast Cancer, Las Vegas, NV (Imedex)

2007 Treatment Implications of Basal-like Biology / NIH Meeting / Health Disparities in Estrogen Receptor Negative Breast Cancer Think Tank
National Cancer Institute, Bethesda, MD

2007 BRCA and other Germline Mutations: Biology and Management Strategies / Conference
Adjuvant, Neoadjuvant Therapies Conference, New York, NY

2007 (1) Inherited Predisposition: A Constellation of Factors
(2) Who is at Risk for Breast Cancer? Tailoring Prevention and Screening / Symposium
Reves International Biennial Breast Cancer Symposium, Dallas, TX

2008 Prophylactic Interventions for the High Risk Patient / Conference
Western Ohio Breast Conference, Dayton, OH

2008 (1) Genetic Testing for Rare Syndromes: Working with Families with Limited Information Discussant, (2) Local Drug Delivery to the Breast: A Phase I Study of Breast Intraductal Cytotoxic Administration Prior to Mastectomy Clinical Management Based on Risk / Annual Meeting
American Association of Cancer Researchers, San Diego, CA

2008 Using Genetic Information in the Management of Patients with Breast Cancer / Annual Meeting
American Society of Clinical Oncology, Chicago, IL

2008 Novel Treatment Strategies for Basal-Like Breast Cancer / Congress
7th Int'l Congress: The Future of Breast Cancer, Kauai, HI
(PER – Physicians' Education Resource)

2008 (1) Genetic Risk Factors for Breast Cancer
(2) Special Session: Career Choices and Challenges in Breast Oncology / Annual Symposium
2008 Breast Cancer Symposium, Washington, DC

2008 Multidisciplinary Management of Inherited Breast Cancer Syndromes / Annual Meeting
Breast Cancer Family Registry, San Antonio TX

2008 Evolution of Breast Cancer Genetics / Medical Grand Rounds
The NIH Clinical Center Grand Rounds Great Teachers Series, National Cancer Institute and the Johns Hopkins University School of Medicine, Washington, DC

2008	Challenges in Triple Negative Breast Cancer / San Antonio Breast Cancer Symposium Review Fletcher Allen Healthcare, University of Vermont, Burlington, VT
2009	Impact of Genetics on Breast Cancer Care / Surgical Grand Rounds (Pappamarkou Lecture) Memorial Sloan Kettering Cancer Center, New York, NY
2009	Breast Cancer Genetics – Beyond BRCA 1 and BRCA 2 / Annual Meeting American College of Medical Genetics Annual Clinical Genetics, Tampa, Florida
2009	Key Findings in Risk, Prevention and Survivorship / CME Program 6th Annual Best of San Antonio, Chicago, IL
2009	Breast Cancer Genetics: Beyond BRCA1 and BRCA2 / Annual Meeting American College of Medical Genetics, Tampa, FL
2009	Reducing Cancer Risk – Progress, Obstacles and Opportunities / Annual Meeting American Association for Cancer Research, Denver, CO
2009	Should Treatment of BRCA-Associated Breast Cancer Be Different / CME Program 20th Anniversary Celebration, Kansas Masonic Cancer Center, Kansas City, KS (Physicians' Education Resource)
2009	The Expanding Role of Cancer Genetics in Oncology / Plenary Lecture / Annual Meeting Duke Comprehensive Cancer Center, Durham, NC
2009	Genetic Etiology and Pathogenesis of Breast Cancer Risk / Symposium ASCO 2009 Breast Cancer Symposium, San Francisco, CA.
2009	Familial Cancer Syndromes / Course George Washington University Hematology and Medical Oncology Best Practices / Washington, DC
2010	What is new in epidemiology, risk factors and prevention of breast cancer / Conference Molecular Markers and Management of Breast Cancer / Mayo Clinic, Jacksonville, Florida
2010	Breast Cancer Genetics / Hematology / Oncology Grand Rounds Maimonides Medical Center, New York, NY

2010	Triple-negative-resistant breast cancer: How do we best manage these patients? Do we use different tests? Do we use systemic therapies? / Symposium 3d Annual Symposium on Personalized Therapies / La Jolla, CA (Oncology Learning Center)
2010	Expanding Role of Clinical Breast Cancer Genetics in Oncology / Cancer Center Seminar Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
2010	Evolution of Clinical Breast Cancer Genetics / Breast Cancer Research Group Seminar Series Washington University Medical Center, St. Louis, MO
2010	Breast Cancer Genetics / Oncology Grand Rounds Columbia University School of Medicine, New York, NY
2010	Breast Cancer Genetics / Breast Tumor Board North Shore-Long Island Jewish Medical Center Tumor Board, Great Neck, NY
2010	Li Fraumeni Syndrome: When to Test / Annual Education Conference National Society of Genetic Counselors, Dallas, Texas
2010	Li Fraumeni Syndrome: When to Test / Annual Education Conference National Society of Genetic Counselors, Dallas, Texas
2010	Identifying a Consortium-Wide Screening Program / Research Conference Li Fraumeni Clinical Research Conference, Bethesda, MD
2010	PARP Inhibitors: Early Promise in Breast and Ovarian Cancer Prevention AACR Annual Frontiers in Cancer Prevention Research, Philadelphia, PA
2010	Screening for Breast Cancer San Antonio Breast Cancer Symposium, San Antonio, TX
2011	Clinical Evolution of Breast Cancer Genetics / Bernard Fisher Lecture University of Pittsburgh Medical Center, Pittsburgh, PA
2011	Targeting Breast DNA Repair and Mitosis in Breast and Ovarian Cancers

AACR Annual Meeting, Orlando, FL

2011 Integrated Discovery Platforms and Personalized Medicine
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

2011 Clinical Development of PARP Inhibitors: Current Status
ASCO Annual Meeting, Chicago, IL

2012 Evolution of Clinical Breast Cancer Genetics
Cancer Center Grand Rounds
Thomas Jefferson University Medical School, Philadelphia, PA

2012 DNA damaging agents in breast cancer: cis-platinum
Cancer Risk and Prevention
Gordon Research Conference: DNA Damage, Mutation & Cancer
Ventura, CA

2012 Li-Fraumeni Syndrome Update
University of Chicago Cancer Center Genetics Conference, Chicago, IL

2012 Cancer Genetics as a Tool for Cancer Prevention
CPRIT Annual Meeting, Austin, TX

2013 Genetic Risk Factors
Cancer and Thrombosis: Balancing Scientific Progress and Personalized Medicine
Duke University Medical Center, McLean, VA

2013 Clinical Studies
AACR Synthetic Lethal Approaches to Cancer
Seattle, WA

2013 Ethics and Genomics
ASCO Annual Meeting
Chicago, IL

2013 Familial Cancer Syndromes
2013 Hematology and Medical Oncology Best Practices
Arlington, VA

2013 Genes
BCRF Scientific Symposium
New York, NY

2014 Risk Reduction in Hereditary Breast Cancer Syndrome
AACR Cancer Susceptibility Conference

San Diego, CA

2014 Clinical Management of Hereditary Breast and Ovarian Cancer Part 1
City of Hope Conference
Duarte, CA

2014 The Evolution of Clinical Cancer Genetics
City of Hope Conference
Duarte, CA

2014 Pharmacogenomics of Breast Cancer Treatment
Cancer Genomics Conference
Chicago, IL

2014 Targeted Therapies: What we've learned from BRCA1/2
Basser Research Symposium
Philadelphia, PA

2014 Familial Cancer Syndromes
2014 Hematology and Medical Oncology Best Practices Course
Washington, DC

2014 Overview and Advancements of Therapeutic Interventions
20th Anniversary BRCA Gene Symposium
Cedars-Sinai, Los Angeles, CA

2014 Evolution of Cancer Genetics 2014
University of Michigan Cancer Center Fall Research Symposium
University of Michigan Cancer Center, Ann Arbor, MI

2014 Advances in Germline Genetics: What Surgeons Need to Know
American College of Surgeons 2014 Clinical Congress
San Francisco, CA

2015 Breast Cancer Risk Assessment and Genetic Testing
The 20th Annual Multidisciplinary Symposium on Breast Disease
University of Florida, Amelia Island, FL

2015 Clinical Follow up of High Risk Patients: What to do with Mutations other than BRCA
The 20th Annual Multidisciplinary Symposium on Breast Disease
University of Florida, Amelia Island, FL

2015 The Evolving Role of cancer Genetics in Breast/Ovarian Cancer Care
Janet Rowley Research Day
The University of Chicago, Chicago, IL

2015 Germline Cancer Genetics in Precision Medicine
7th Annual Niehaus Southworth Weissenbach Award and Lecture
Memorial Sloan Kettering Cancer Center

2015 Genetics Diversity Among Breast Cancers
American Society for Investigative Pathology - Annual Meeting,
Boston, MA

2015 Breast and Ovarian Cancer Genetics 2015: New Testing, New Uses
Stamford Hospital, Stamford, CT

2015 Precision Medicine: Intentional and Incidental Germline Testing
American Association for Cancer Research - Annual Meeting,
Philadelphia, PA

2015 Germline Cancer Genetics in Precision Medicine
National Institutes of Health Wednesday Afternoon Lecture Series
Bethesda, MD

2015 Genetics and Genomics for the Practicing Clinician Seminar
American Society of Clinical Oncology Annual Meeting
Chicago, IL

2015 Update on Screening and Surveillance for BRCA Carriers: It's not Just Ovarian Cancer
American Society of Clinical Oncology Annual Meeting
Chicago, IL

2015 Cancer Prevention, Genetics, and Epidemiology Highlights Session
American Society of Clinical Oncology Annual Meeting
Chicago, IL

2015 High Risk Genetic Syndromes: When to Refer Families for Screening?
American Society of Clinical Oncology Annual Meeting
Chicago, IL

2015 Chemoprevention for Breast and Ovarian Cancer
American Society of Clinical Oncology Annual Meeting
Chicago, IL

2015 Germline Cancer Genetics in Precision Medicine
Dr. Charles LeMaistre Lecture in Oncology and Cancer Prevention
MD Anderson Cancer Center
Houston TX

2015 Familial Cancer Syndromes
2015 Hematology and Medical Oncology Best Practices Course
George Washington University
Arlington, VA

2015 Evolution of Genetic Testing for Hereditary Breast/Ovarian Cancer Susceptibility
Henry T. Lynch Symposium, Creighton University
Omaha, NE

2015 Genetic Risk for Breast Cancer Beyond BRCA
The GenomeFIRST Symposium, Geisinger Health System
Scranton, PA

2015 What Can We Learn from Variants and Incidental Findings?
Collaborative Group of the Americas Annual Meeting
Baltimore, MD

2015 Evolution of Cancer Genetics: Should We Test Everyone?
American Clinical and Climatological Association
Ponte Vedra, FL

2015 Recent Evolution of Germline Cancer Genetics
Northwestern University, Grand Rounds
Chicago, IL

2016 Cancer Genetics: New Opportunities and Challenges
Herbert Irving Comprehensive Cancer Center Distinguished Seminar Series
New York, NY

2016 Cancer Genetics: New Opportunities and Challenges
Sidney Kimmel Cancer Center, Grand Rounds
Philadelphia, PA

2016 Update on Inherited Cancer Genetics
Scientist Survivor Program, AACR Annual Meeting
New Orleans, LA

2016 Putting Genetic Data into Perspective for Future Trials in Prostate Cancer
American Society of Clinical Oncology Annual Meeting
Chicago, IL

2016 Familial Cancer Syndromes
Hematology/Oncology Board Review Course

George Washington University Medical Center, Washington, DC

2016 Overview of Current & Future Landscape in Cancer Genetics
Cancer Genetics: Finding Meaning in Tumor and Germline Genomes
UT Southwestern Medical Center, Dallas, TX

2016 New Horizons in Prevention//Special challenges and opportunities in inherited risk syndromes
Stand Up to Cancer Summit, La Jolla, CA

2017 Developments in Breast Cancer Genetics 2017
Ground Rounds Lecture
Indiana University Simon Cancer Center, Indianapolis, IN

2017 Is there a glass ceiling in oncology?
Margaret L. Kripke Legend Award Lecture
MD Anderson Cancer Center, Houston, TX

2017 Novel approaches to prevention in inherited cancer syndromes
AACR Annual Meeting, Washington, DC

2017 Should Cancer Genetic Testing Be Offered to Everyone Regardless of Family History?
AACR Annual Meeting, Washington, DC

2017 Cancer Genetics Comes of Age
Joseph H. Burchenal Award Lecture
AACR Annual Meeting, Washington, DC

2017 Progress in Epidemiology of Li Fraumeni Syndrome
Basser Center for BRCA, Philadelphia, PA

2017 Prevention of invasive breast cancer: new opportunities (Panelist)
ASCO Annual Meeting, Chicago, IL

2017 What's New in HBOC Research?
FORCE Conference, Orlando, FL

2017 Cohorts, Specimens and Other Biological Resources (session chair)
Think Tank Meeting on The Molecular Atlas of Precancers (MAP)
National Cancer Institute, Washington, DC

2017 Precision Medicine: From Technology to Decision: What Does It Take?
AACR Integrative Molecular Epidemiology Workshop
Boston, MA

2017 Familial Cancer Syndromes
Hematology/Oncology Board Review Course
George Washington University Medical Center, Washington, DC

2017 Progress and Challenges in Germline Genetic Testing
Huntsman Cancer Institute Symposium
University of Utah
St. Lake City, Utah

2017 Progress and Challenges in Germline Genetic Testing
Mount Auburn Hospital
Cambridge, MA

2017 Managing increased breast cancer risk based on high and moderate penetrance gene mutations
San Antonio Breast Cancer Symposium
San Antonio, TX

2017 The Promise of PARP Inhibitors in Metastatic Breast Cancer: New Data, New Treatments?
Medscape CME Live Symposium at the San Antonio Breast Cancer Symposium (Medscape - WebMD)

2018 Current Challenges in Breast Cancer Genetics
Human Cancer Genetics Keynote
The Ohio State University

2018 Data and bias in the development of PARP inhibitors for cancer treatment
Longwood Translational Medicine China Initiative
Boston, MA

2018 Overview of Breast Cancer Genetics-From Inception to Current Day
2018 Consortium of Breast Centers Conference
Las Vegas, NV

2018 Novel Breast Cancer Genes & Impact on Breast Cancer Prognosis
Masters Lecture
2018 National Consortium of Breast Centers Conference
Las Vegas, NV

2018 Management of Patients with Moderate Penetrant Cancer Predisposition Diseases
Webinar (Ambry Genetics)

2018 Cancer Genetics: Update for Breast Cancer Care (moderator)

San Antonio Breast Cancer Symposium
San Antonio, TX

2019 Management of non-BRCA 1,2 Mutation Carriers
The 24th Annual Multidisciplinary Symposium on Breast Disease
University of Florida, Amelia Island, FL

2019 Breast Cancer Genetics 2019: Where are we and where do we need to go
The 24th Annual Multidisciplinary Symposium on Breast Disease
University of Florida, Amelia Island, FL

2019 Using Genetics for Therapeutic Decisions
The 24th Annual Multidisciplinary Symposium on Breast Disease
University of Florida, Amelia Island, FL

2019 What's new in cancer genetics 2019?
Rutgers Cancer Institute of New Jersey
Brunswick, New Jersey

2019 Breast Cancer: Updates in testing and management of BRCA mutations
72nd Annual Cancer Symposium
San Diego, California

2019 Genotypes, Phenotypes, and the evolving Clinical Picture of TP53
City of Hope Cancer & Genomics Conference
Duarte, California

2019 Keynote Updates on Managing Hereditary Breast Ovarian Cancer
City of Hope Cancer & Genomics Conference
Duarte, California

2019 Updates in Cancer Genetics, Grand rounds lecture
Georgetown-Lombardi Comprehensive Cancer Center
Washington, DC

2019 ASCO-American Cancer Society Award Lecture
ASCO Annual Meeting
Chicago, IL

2019 Precision Medicine - From Technology to Decision: What does it take?
AACR Integrative Molecular Epidemiology Workshop:
Bridging Cancer Biology and Precision Medicine
Boston, MA

2019 Progress and Challenges in Clinical Cancer Genetics
Fox Chase Cancer Center Distinguished Lecture Series
Philadelphia, Pennsylvania

2019 Breast Cancer Prevention, Session Moderator
San Antonio Breast Cancer Symposium
San Antonio, TX

2020 Evolution of Cancer Genetics
Grand Rounds Lecture, Johns Hopkins
Baltimore, MD

2020 Reconsidering cancer genetics after MultiGene Panel Testing
Johns Hopkins Visiting Professor Lecture Series
Baltimore, MD

2020 Rethinking Li Fraumeni Syndrome (SBLA) 50 Years Later
9th Annual Cancer Genetics and Genomic Conference
Chicago, IL

2020 New Therapies for Metastatic BRCA -Mutant and Other Germline-Mutant Breast Cancers
19th Annual International Congress on the Future of Breast Cancer
New York, NY (Virtual)

2020 Debate: All Breast Cancer Patients Should Have Germline Genetic Testing, Session Moderator
San Antonio Breast Cancer Symposium
San Antonio, TX

2021 Evolution of Breast cancer Genetic Testing in the US
University of Florida 26th Annual Multidisciplinary Symposium on Breast Disease
Jacksonville, Florida

2021 Evolution of Clinical Cancer Genetics
New York University Grand Rounds
New York City, New York

2021 The Evolution of Breast Cancer Genetics
Kansas University Cancer Center Seminar Series
Lawrence, Kansas

2021	Unexpected Consequences of Expanded Germline Genetic Testing Stanford Frontiers in Oncology Seminar Stanford, California
2021	NCAB-BSA Cancer Prevention Working Group Report NCI Division of Cancer Prevention "Investigators' and Site Coordinators' Opportunity for Research Excellence I-SCORE" 2021 Virtual Meeting
2021	Redefining LFS using clinical and molecular data MDACC Genetics of Hereditary Cancer Symposium: Honoring Louise C. Strong, M.D.
2021	2nd Annual Franco Muggia Award and Lecture: Genetic Testing Comes of Age in Breast and Ovarian Cancer 4th Annual Pink and Teal Conference

International

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

1997	Predisposition Testing for the Li-Fraumeni Cancer Syndrome / Symposium Paterson Symposium on Li Fraumeni Syndrome, Manchester, England (UK)
1998	(1) Issues in Assessment and Management of Hereditary Breast Cancer (2) Breast Cancer Genetics / Conference 1st Milan Breast Cancer Conference, Milan, Italy
1999	Genetics of Breast Cancer / Conference 6th International Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland
2000	Tumor Prevention and Genetics / Conference First Annual International Conference on Cancer Prevention, St. Gallen, Switzerland
2000	Women's Health in the New Millennium-Breast Cancer Prevention / Course New England Journal of Medicine, International Course on Women's Health, Paris, France
2001	Hereditary Breast Cancer / Conference 7th International Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland

2001	Genetics of Ovarian Cancer: Remaining Questions / Annual Meeting Society of Gynecologic Oncology; Toronto, Canada
2003	Challenges in Breast Cancer Genetics / Symposium "Think Tank 13" Breast Cancer Symposium St. Kitts, Federation of St. Kitts and Nevis
2003	Genetic Markers of Breast Cancer and Their Clinical Relevance / Conference 8th International Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland
2003	The Limited Role of Genetic Risk – Hereditary Breast Cancer: An Identifiable High Risk Group / Conference 5th Milan Breast Cancer Conference, Milan, Italy
2004	High Risk Women – Assessing and Managing Breast Cancer Risk / Conference 2nd Inter-American Breast Cancer Conference, Cancun, Mexico
2005	Counseling Issues in Hereditary Cancer Predisposition / Conference 9th International Conference on the Psychosocial Aspects of Genetic Testing, Philadelphia, PA
2005	Genetic Counseling: Therapeutic Consequences / Conference 9th St. Gallen International Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland
2006	(1) Genetic Risk Assessment and Beyond: Anything New? / (2) Defining Risk Groups and Beyond/ Panel Co-Chair and Speaker Defining Risk Groups and Beyond / Conference 9th. Gallen International Conference on Cancer Prevention, St. Gallen, Switzerland
2006	Prophylactic Surgery and Oophorectomy in the Management of High Risk Individuals / Conference European Breast Cancer Conference, Nice, France
2006	(1) Cancer Genetics (2) Breast Cancer Screening / Symposium Genetics in Medicine Symposium, Santiago, Chile
2006	Update on Genetics of Breast Cancer / Conference Second Joint American-Israeli Conference on Cancer, Jerusalem, Israel
2006	The Use of Adjuvant Hormonal Therapy for Breast Cancer / Course

IISS Course on Breast Cancer & Melanoma: Biology, Diagnosis and Therapy, Varese, Italy

2006 Women at High Risk of Breast Cancer: Who are they? What Medical Strategies Do We Have for Reducing Cancer Risk? / Symposium
Hereditary Cancer Symposium, Barcelona, Spain

2006 (1) Ovarian Suppression in Premenopausal Breast Cancer (2) Familial Cancer Session – Overview (3) Do the Long Term Effects of Chemotherapy Matter? / Congress
Third Australian Health & Medical Research Congress, Melbourne, Australia

2007 Biology of Breast Cancer Genes and Beyond / Conference
10th International Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland

2007 (1) Assessment and Management of Women at High Risk
(2) Optimal Treatment for Basal-like Tumors / Conference
VII Madrid Breast Cancer Conference, Madrid, Spain

2007 Support for Potential Surveillance Strategies for Members of LFS Kindreds / Workshop
3rd International Workshop on Mutant p53, Lyon, France

2007 Treatment of BRCA1 and BRCA2-related Breast Cancer with Existing Agents / Symposium,
Hereditary Breast and Ovarian Cancer(HBOC) New Frontiers in Research and Practice Symposium / Montreal, Quebec, Canada

2007 Is Our Research Leading to Better Genetic Markers that Help People Reduce Their Risk? / Conference
3rd Haifa Cancer Prevention Conference, Haifa, Israel

2008 Cancer Prevention and Genetic Testing: An Update / Conference
5th International Conference on Cancer Prevention, St. Gallen, Switzerland

2008 Genetic Predisposition: BRCA 1, BRCA 2 and Others / Conference
10th Milan Breast Cancer Conference, Milan, Italy

2008 High-Penetrance Genes / Conference
Japan Cancer Association/ American Association for Clinical Research Special Joint Conference, Osaka, Japan

2008 (1) Approach to the Woman at High Risk of Breast and Ovarian Cancer / Keynote Speaker (2) Familial Cancer and Genetics (3) Managing Menopausal Symptoms in the Breast Cancer Setting / (4) An American Model of Multidisciplinary Breast Cancer Care / (5) Gene Profiling / Plenary Speaker (6) Adjuvant Chemotherapy – My Approach /Plenary Speaker / Conference
Leura VI International Breast Cancer Conference, Sydney, Australia

2009 Implications of Inherited Predispositions for Surveillance, Risk Reduction and Treatment / Panel Moderator and Speaker / Conference
11th International Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland

2009 Alkylating Agents / Conference
IMPAKT Breast Cancer Conference, Brussels, Belgium

2009 Assessment of High-Risk Women for Breast Cancer / Conference
VIII Madrid Breast Cancer Conference, Madrid, Spain

2009 A General Overview of Hereditary Breast and Ovarian Cancer / Salvatore Venuto Lecture / Course
1st Magna Graecia Advanced Course: Hot Topics in Translational Oncology – Hereditary Breast and Ovarian Cancer, Catanzaro, Italy

2010 Implications of Breast Cancer Genetics for Patient Management / Medical Oncology Grand Rounds
Princess Margaret Hospital, Toronto, Ontario, Canada

2010 Translational Implications / Conference
IMPAKT Breast Cancer Conference, Brussels, Belgium

2010 (1) Risk for Breast Cancer: Classification and Its Management in High Risk Women (2) Management of Patients with Breast Cancer and BRCA 1 / 2 Mutations, Including Contra-Lateral Breast (3) Advances in Breast Cancer / Conference
VII Breast Cancer Symposium, Santiago, Chile

2010 High-Risk Genes for Breast Cancer: The Genetic Foucault Pendulum / Conference
12th Milan Breast Cancer Conference, Milan, Italy

2010 (1) Conventional Chemotherapy and non-PARP Targeted Strategies for BRCA – Deficient Breast Cancer (2) Role of PARP Inhibitors in Breast and Ovarian Cancer / Meeting
Clinical Dilemmas in Management of Breast and Ovarian Cancer in BRCA Carriers, Tel Aviv, Israel (Prime Oncology)

2011	Prevention of Breast Cancer / Workshop Translational Cancer Prevention Workshop & Biomarkers Workshop 2011: 1st Indo-USA Initiative, Bangalore, India
2011	Platinums in the Treatment of Triple Negative Breast Cancer / Conference Breakthrough Breast Cancer Research Centre Triple Negative Breast Cancer, London, UK
2011	Germline Genetic Predisposition: Treatment Options / Conference 12th St. Gallen International Breast Cancer Conference, St. Gallen, Switzerland
2011	Germline in Personalized Cancer Medicine / Symposium Novartis Cancer and Epigenetics Symposium, Shanghai, China (Novartis)
2012	Inducing BRCAness in BRCA-1 Proficient Tumors / Annual Meeting BIG-NABCG, Brussels, Belgium
2012	Resurgence of interest in Platinums in Breast Cancer Treatment XI International Symposium on Platinum Compounds Verona, Italy
2012	Clinical Cancer Genetics in the era of Genomics NCRI National Cancer Research Meeting Liverpool, England, UK
2012	Evaluation and Management of Hereditary Breast Cancer Risk Young Women's Breast Cancer Conference Dublin, Ireland
2013	Clinical Impact of Unclassified BRCA-Variants and Thrapeutics for Patients with Germline Mutations 13th International St. Gallen Breast Cancer Conference St. Gallen, Switzerland
2013	Evolution of Cancer Genetics in the Era of Genomics Distinguished Lecture Series of the German Cancer Research Center Heidelberg, Germany
2013	Germline Mutations and Breast Cancer 15th Milan Breast Cancer Conference Milan, Italy

2013	BRCA Germline Genetics Influencing 7th Annual Frontiers of Clinical Investigations: Bench to Bedside Symposium La Jolla, CA
2013	The Future of Cancer Research 2013 Canadian Cancer Research Conference Toronto, Canada
2014	Treatment of Hereditary Breast Cancer Living with BRCA Public Symposium Montreal, Canada
2014	Old and New Treatments for Hereditary Breast and Ovarian Cancer Living with BRCA Public Symposium Montreal, Canada
2014	Unclassified Variants of BRCA 1 and BRCA 2 16th Milan Breast Cancer Conference Milan, Italy
2014	Germline Genomics - Cancer Panel Testing; Practical Implications for Clinical Practice kConFab Annual Meeting 2014 New South Wales, Australia
2014	Systemic Therapies in BRCA+ Breast Cancer – What's New? 2nd Breast Cancer in Young Women Conference Dublin, Ireland
2015	Using Germline Genetics in the Management of Breast Cancer Patients and Their Families 14th International St. Gallen Breast Cancer Conference St. Gallen, Switzerland
2015	The Impact of Germline Genetics on Breast Cancer Risk and Intefration in Clinical Practice/Clinical Interpretation IMPAKT International Breast Cancer Conference Brussels, Belgium
2016	Handling Carriers of Breast-Ovary Syndrome Founder Populations Conference Haifa, Israel
2017	The risks and benefits of panel germline testing in breast cancer 15th International St. Gallen Breast Cancer Conference

St. Gallen, Switzerland

2017 What should oncologists know about breast cancer genetics in 2017
IEO Veronesi Breast Cancer Award Lecture
17th Milan Breast Cancer Conference, Milan, Italy

2017 PARP Inhibitors
European Society of Medical Oncology Meeting 2017
Madrid, Spain

2017 The Minimum Criteria to Indicate a Genetic Risk Assessment
Concepts of cancer genetics applied to the management of patients with hereditary breast and ovarian cancer syndrome
XX Brazilian Congress of Clinical Oncology Meeting
Rio de Janerio, Brazil

2017 Current Challenges in Cancer Genetics
2nd International Conference on Founder Populations
Kochi, Kerala, India

2018 Opportunities for cancer risk-reduction in inherited breast and ovarian cancer predisposition
German Cancer Research Center (DKFZ) on Preventative Oncology
Heidelberg, Germany

2018 Managing hereditary risk of Prostate and Breast Cancer
Connie Johnson Memorial Lecture
Garvan Institute
Sydney, Australia

2018 Evolving phenotype of LFS: data from panel testing
Li Fraumeni Syndrome Association Symposium
Toronto, Canada

2018 Clinical management of women harboring low-moderate risk genes
4th Breast Cancer in Young Women Conference
Lugano, Switzerland

2019 Treatment selection for patients with BRCA mutation
16th International St. Gallen Breast Cancer Conference
St. Gallen, Switzerland

2020 Genetics and Breast Cancer Risk
UK Interdisciplinary Cancer Symposium
Birmingham, United Kingdom

2020	Familial and hereditary breast cancer BCY5 Symposium Milan, Italy (Virtual)
2020	Evolution of genetic testing for HBOC in the US Global Conference on Breast Health Japan (Virtual)

Report of Clinical Activities and Innovations

Current Licensure and Certification

1984	American Board of Internal Medicine Certificate
1984	Massachusetts Medical Licensure
1987	American Board of Internal Medicine, Medical Oncology Certificate
1988	American Board of Internal Medicine, Hematology Certificate

Practice Activities

1. Clinical Practice

1987 -	Ambulatory Outpatient clinics	Breast medical oncology DFCI, Boston, MA	Two sessions per week (2 new patients, 16 follow-up patients per week)
1991 -	Ambulatory Outpatient clinics	Cancer risk and prevention (focus on genetics and risk reduction) DFCI	Two sessions per week (10 new patients, 14 follow-up patients per week.)
1992 -	Attending physician inpatient service	Solid tumor oncology inpatient service Brigham & Women's Hospital, Boston, MA	Two weeks per year

2. Clinical Innovations

Breast Cancer Risk and Prevention Program	I developed and lead the Cancer Risk and Prevention which evaluates and follows women with a family history of breast and/or ovarian cancer. The clinic was one of the first of its kind in the world, and has been visited by numerous geneticists and oncologists as they start their own cancer genetics activities

Women's Cancer Program	Senior leader in the development and ongoing evolution of a multidisciplinary center that provides state-of the art care for women with breast and ovarian malignancies. The program provides patient with comprehensive and cutting edge treatment including therapies available only through participation in clinical trials. Member, Steering Committee, Women's Cancer Program

Report of Education of Patients and Service to the Community

Committees

2007 – 2009 –	Board of Directors	Facing Our Risk of Cancer Empowered (FORCE), Member, Planning Committee, FORCE Conferences Tampa, FL
2004 –	Medical Advisory Board	Young Survival Coalition, New York, NY

Invited Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.

2006 Hereditary Cancer: Past, Present and Future / Speaker
FORCE Conference on Hereditary Breast and Ovarian Cancers, Tampa, FL

2007 High-risk Without Cancer/Pre-vivors / Speaker
FORCE Conference on Hereditary Breast and Ovarian Cancers, Tampa, FL

2008 Cancer Advances / Public Forum / Speaker
2008 ASCO Breast Cancer Symposium, Washington, DC

2008 High-Risk Without Cancer/ Pre-vivors / Speaker
FORCE Joining Forces Against Hereditary Cancer Conference, Tampa FL

2009 Cancer Risk – Progress, Obstacles and Opportunities / Speaker
National Breast Cancer Coalition Fund, Annual Advocacy Training Conference, Washington, DC

2009 Cancer Advances Panel / Moderator / Risk in General as Well as Genetic Risk / Speaker
A Public Forum on Breast Cancer / ASCO 2009 Breast Cancer Symposium, San Francisco, CA

2009 Breast Cancer Awareness / Prevention and Screening Methods /Speaker
St. Ambrose Family Shelter, Boston, MA

2009 What's in Your Genes / Community Education /Speaker
Exeter Hospital, Exeter, NH

2010 (1) Treating Advanced Breast Cancer: Medical and Research News / Speaker
(2) Bone Mets: Treatments and Strategies Workshop / Speaker
4th Annual Conference for Women Living with Advanced Breast Cancer: Enhancing Your Health and Quality of Life
West Conshohocken, PA

2010 BRCA and Triple Negative Breast Cancer / Speaker
Joining FORCEs Against Hereditary Cancer
Orlando, FL

2010 What's New in the Care of Patients with Breast Cancer: Medical Care / Speaker
South Shore DFCI/BWH Cancer Center Community Education Program, South Weymouth, MA

2011 Genetics of Breast Cancer and Beyond: Updates Through a Jewish Lens / Speaker
Combined Jewish Philanthropies, Jewish Women Connect Conference, Dedham, MA

2019 Panelist – OneInForty Spring Symposium 2019
Temple Emmanuel, Newton, MA

2019 Clinical Trials for patients with dense breasts
BPREP Patient Forum
Dana-Farber Cancer Institute, Boston, MA

2020 BRCA ½ ad the Jewish Community: where we are today
Temple Beth Avodah
Newton, MA

2020 Impact of covid-19: living with hereditary cancer – what you need to know
Oneinforty
Webinar

2021 Understanding the Jewish-Cancer Connection
Oneinforty
Webinar

2021 Breast Cancer Genetics: The Essentials of What You Absolutely Need to Know About Breast Cancer Genetics
4th Annual BPREP Patient Forum
Dana-Farber Cancer Institute, Boston, MA

Report of Scholarship

Peer-Reviewed Publications in Print or Other Media

Research Investigations

1. Blattner WA, **Garber JE**, Mann DL, McKeen EA, Henson R, McGuire DB, Fisher WB, Bauman AW, Goldin LR, Fraumeni JF Jr. Waldenstrom's macroglobulinemia and autoimmune disease in a family. Ann Intern Med. 1980; 93:830-2.

2. **Garber JE**, Wright AM. Unilateral spondylolysis and contralateral pedicle fracture. Spine 1986; 11:63-6.

3. Rosenberg AE, **Garber JE**, Bennet W, Bhan AK, Antman KH, Mark EJ. Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. Am J Clin Path 1988; 90:723-6.

4. **Garber JE**, Li FP, Kingston JE, Krush AJ, Strong LC, Finegold MJ, Bertario L et al. Hepatoblastoma and familial adenomatous polyposis. J Natl Cancer Inst 1988; 80:1626-8.

5. **Garber JE**, Shipley W. Carcinoma of the gall bladder in 3 members of a family. Cancer Genet Cytogenet 1989; 39:41-2.

6. Li FP, **Garber JE**, Dreyfus MG, Blattner WA, Fraumeni JF Jr, Sandberg AA. Follow-up of a cancer family with in-vitro radioresistance. Lancet 1990; 335:176-7.

7. **Garber JE**, Burke EM, Lavally BL, Billett AL, Sallan SE, Scott RM, Kupsky W, Li FP. Choroid plexus tumors in the breast cancer - sarcoma syndrome. Cancer 1990; 66:2658-60.

8. **Garber JE**, Liepman MK, Gelles EJ, Corson JM, Antman KH. Melanoma and soft tissue sarcoma in seven patients. Cancer 1990; 66:2432-4.

9. Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, **Garber JE**, Henderson IC, Navari RM, Miller AA. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endo Metab. 1991; 73:99-106.

10. **Garber JE**, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP. A follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991; 5151:6094-7.

11. Grundy P, Telzerow P, Haber D, Berman B, Abramowsky C, Norris D, Li F, Patterson M, **Garber J**. Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms. Lancet 1991; 338: 1079-80.

12. Borresen AL, Andersen TI, **Garber J**, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, Friend SH. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992; 52:3234-6.

13. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen A-L, Li FP, **Garber J,** Strong LC. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992; 326:1309-15.

14. Biesecker BB, Boehnke M, Calzone K, Markel DS, **Garber JE**, Collins FS, and Weber BL. Genetic counseling for families with inherited susceptibility to breast cancer and ovarian cancer. JAMA 1993; 269:1970-4.

15. Chamberlain JS, Boehnke M, Frank TS, Kiovsis S, Xu J, Guo SW, Hauser ER, Norum RA, Helmbold EA, Markel D, Keshavarzism, Jackson CE, Calzone K, **Garber JE**, Collins FS, Weber BL. BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis. Am J Hum Genet 1993; 52:792-8.

16. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, **Garber JE**, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027-38.

17. Hoskins KF, Stopler JE, Calzone KA, Merajver SD, Rebbeck TR, **Garber JE**, Weber BL. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995; 273:577-85.

18. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BA, Weber BL, **Garber JE,** Birch JM, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56:254-64.

19. Couch FJ, **Garber J,** Kiousis S, Calzone K, Hauser ER, Merajver SD, Frank TS, Boehnke M, Chamberlain JS, Collins FS, et al. Genetic analysis of eight breast-ovarian cancer families with suspected BRCA1 mutations. J Natl Cancer Inst Monogr 1995: 9-14.

20. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, **Garber JE,** Collins FS, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995; 1:539-44.

21. Frebourg T, Barbier N, Yan YX, **Garber JE**, Dreyfus M, Fraumeni J, Jr, Li FP, Friend SH. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995; 56:608-15.

22. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein D, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, **Garber JE**, Duda RB, Mayzel KA, Isselbacher KJ. Germ-Line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334:143-9.

23. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Holt MS, Sedlacek S, Rommens J, Simard J, **Garber J**, Merajver S, Weber B. BRCA2 Germline Mutations in Male Breast Cancer Cases and Breast Cancer Families. Nature Genetics 1996; 13:123-5.

24. Patenaude AF, Schneider KA, Kieffer SA, Calzone KA, Stopfer JE, Basili LA, Weber BL, **Garber JE**. Acceptance of invitations for p53 and BRCA1 predisposition testing: Factors influencing potential utilization of cancer gene testing. Psycho-Oncology 1996; 5:241-50.

25. Rebbeck TR, Couch FJ, Kant J, Calzone K, DeShano M, Peng Y, Chen K, **Garber JE**, Weber BL. Genetic heterogeneity in hereditary breast cancer: Role of BRCA1 and BRCA2. Am J Hum Genet 1996; 59:547-53.

26. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, **Garber JE**, Weber BL, Lynch HT, Boyd J. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335:1413-16.

27. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA, **Garber JE**. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2:1179-83.

28. Foretova L, **Garber JE**, Sandowsky NL, Verselis SJ, Li FP. Prostate-specific antigen in nipple aspirate. Lancet 1996; 347:1631.

29. Rebbeck TR, Walker AH, Phelan CM, Godwin AK, Buetow KH, **Garber JE,** Narod SA, Weber BL. Defining etiologic heterogeneity in breast cancer using genetic biomarkers. Prog Clin Biol Res 1997; 396:53-61.

30. Burke W, Petersen G, Lynch P, Botkin J, Daly M, **Garber J**, Kahn MJ, McTiernan A, Offit K, Thomson E, Varricchio C. Recommendations for follow-up care of individuals

with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277:915-19.

31. Burke W, Daly M, **Garber J**, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 77:997-1003.

32. Schrag D, Kuntz KM, **Garber JE**, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy of women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336:1465-71.

33. Foretova L, **Garber JE,** Sadowsky NL, Verselis SJ, Joseph DM, Andrade AF, Gudrais PG, Fairclough D, Li FP. Carcinoembryonic antigen in breast nipple aspirate fluid. Cancer Epidemiol Biomarkers Prev 1998; 7:195-8.

34. Audrain J, Rimer B, Cella D, **Garber J**, Peshkin BN, Ellis J, Schildkraut J, Stefanek M, Vogel V, Lerman C. Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol 1998; 16:133-138.

35. Hisada M, **Garber JE**, Fung CY, Fraumeni JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90:606-11.

36. Frank TS, Manley SA, Olopade OI, Cummings S, **Garber JE**, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader ST, Offit, K, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16:2417-25.

37. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, **Garber JE**, Tonin PN, Abrahamson Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade OI, Mosiehi R, Liede A, Futreal PA, Weber BL, Lenoir GM, Lynch HT, Narod SA. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 1998; 90:761-6.

38. Chabner E, Nixon A, Gelman R, Hetelekidis S, Recht A, Bornstein B, Connolly J, Schnitt S, Silver B, Manola J, Harris J, **Garber J**. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early stage breast cancer. J Clin Oncol 1998; 16:2045-57.

39. Syngal S, Weeks JC, Schrag D, **Garber JE,** Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998; 129:787-96.

40. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, **Garber J,** Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo

MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, Goldgar D, et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998; 62;1381-8.

41. Schwartz MD, Lerman C, Audrain J, Cella D, Rimer B, Stefanek M, **Garber J,** Lin TH, Vogel V. The impact of a brief problem-solving training intervention for relatives of recently diagnosed breast cancer patients. Ann Behav Med 1998; 20:7-12.

42. FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, **Garber JE,** Eng C, Haber DA. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998; 17:727-31.

43. Audrain J, Rimer B, Cella D, Stefanek M, **Garber J**, Pennanen M, Helzlsouer K, Vogel V, Lin TH, Lerman C. The impact of a brief coping skills intervention on adherence to breast self-examination among first degree relatives of newly diagnosed breast cancer patients. Psycho-Oncology 1999; 8:220-229.

44. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MD, Narod SA, **Garber JE**, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor CAG repeat. Am J Hum Genet, 1999; 64:1371-7.

45. Syngal S, Fox EA, Li C, Dovidio M, Eng C, Kolodner RD, **Garber JE.** Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA, 1999; 282:247-53.

46. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C. Olopade O, **Garber JE**, Goodwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-9.

47. Kolodner RD, Tytell JD, Schmeits JL, kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, **Garber JE**, Syngal S, Anton-Culver H, Li FP. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999; 59:5068-74.

48. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, **Garber JE**, Haber DA. Heterozygous germ line hCHK mutations in Li-Fraumeni syndrome. Science 1999; 286:2528-31.

49. Emmons KM, Kalkbrenner KJ, Klar N, Light T, Schneider KA, **Garber JE**. Behavioral risk factors among women presenting for genetic testing. Cancer Epidemiol Biomarkers Prev 2000; 9:89-94.

50. Shafman TD, Levitz S, Nixon AJ, Gibans L-A, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, **Garber J**, Harris JR, Haber DA. Prevalence of germline truncating mutations in *ATM* in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer 2000; 27:124- 9.

51. Schrag D, Kuntz KM, **Garber JE**, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000; 283: 617-24.

52. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, **Garber JE,** Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-19.

53. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, **Garber J**, Berg C, Isaacs C, Heimann R, Olopade O, Haffty B, Weber BL. Effect of radiotherapy following breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000; 18:3360-9.

54. Schrag D, Kuntz KM, **Garber JE**, Weeks JC. Benefit of prophylactic mastectomy for women with BRCA1 or BRCA2 mutations. JAMA 2000; 283:3070-2.

55. Rohlfs EM, Puget N, Graham ML, Weber BL, **Garber JE**, Skrzynia C, Halperin JL, Lenoir GM, Silverman LM, Mazoyer S. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer 2000; 28:300-7.

56. Dorval M, Patenaude AF, Schneider KA, Kieffer SA, DiGianni L, Kalkbrenner KJ, Bromberg JI, Basili LA, Calzone K, Stopfer J, Weber BL, **Garber JE**. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol 2000; 18:2135-42.

57. Syngal S, Schrag D, Falchuk M, Tung N, Farraye FA, Chung D, Wright M, Whetsell A, Miller G, **Garber JE**. Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. JAMA 2000; 284:857-860.

58. Lu KH, **Garber JE**, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 1814:2728-32.

59. Syngal S, Fox EA, Eng C, Kolodner RD, **Garber JE**. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000; 37:641-645.

60. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, **Garber JE**, Haber DA, Polyak K. Phenol sulfotransferases: hormonal

regulation, polymorphism, and age of onset of breast cancer. Cancer Res 2000; 60:6859-63.

61. Lehmann LS, Weeks JC, Klar N, Biener L, **Garber JE**. Disclosure of familial genetic information: perceptions of the duty to inform. Am J Med 2000; 109:705-711.

62. Nichols KE, Malkin D, **Garber JE**, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2000; 10:83-7.

63. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, **Garber J**, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357:1467-70.

64. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, **Garber JE**, Lynch HT, Weber BL, Brown M. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001; 61: 5420-4.

65. Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, **Garber JE**, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001; 61;8062-7.

66. Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, **Garber J**, et al. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics 2001; 11:635-8.

67. Diller L, Nancarrow CM, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, **Garber J.** Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol 2001; 20:2085-91.

68. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, **Garber JE**, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of *BRCA1* or *BRCA2* mutations. N Engl J Med 2002; 346:1616-22.

69. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, **Garber JE**, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20:2701-12.

70. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, **Garber JE**, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Huges KS, Roche CA, Ganz PA, Seldon J Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2

mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002; 94:844-51.

71. Gazzoli I, Loda M, **Garber J**, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002; 62:3925-8.

72. Chen WY, **Garber JE**, Higham S, Schneider KA, Davis KB, Deffenbaugh AM, Frank TS, Gelman RS, Li FP. BRCA1 /2 genetic testing in the community setting. J Clin Oncol 2002; 20:4485-92.

73. Leibowitz SB, **Garber JE,** Fox EA Loda M, Kaufman DS, Kantoff PW, Oh WK. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003; 9:208-12.

74. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, **Garber JE**, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22:1055-62.

75. Syngal S, Bandipalliam P, **Garber J**, Kolodner RD. Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer. Gastroenterology. 2004; 126:936-37.

76. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, **Garber J**, Weber B, Tung N, Horsman D, Isaacs C. Monteiro AN, Sun P, Narod SA. Cancer Variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 2004; 3:1-10.

77. Balmana J, Stoffel EM, Emmons KM, **Garber JE**, Syngal, S. Comparisons of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes. J Med Genet 2004; 41: e44.

78. Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, **Garber J**, Olsson H, Sun P, Narod SA. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Can Inst 2004; 96:1091-4.

79. Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, **Garber JE**, Hawk E, Ganz PA, Somerfield MR; Writing Committee of the ASCO Cancer Prevention Committee. Cancer Prevention and the American Society of Clinical Oncology. J Clin Oncol 2004; 22:3848-51.

80. Schneider KA, DiGianni LM, Patenaude AF, Klar N, Stopfer JE, Calzone KA, Li FP, Weber BL, **Garber JE.** Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test 2004 ; 8 :222-8.

81. Li FP, Fletcher JA, Heinrich MC, **Garber JE**, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD. Familial gastrointestinal stromal tumor syndrome phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23:2735-43.

82. Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, **Garber JE**, Ford JM, Hartman, AR. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14:1082-9.

83. Dahia PL, Ross K, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JA, Tischler A, Hodin R, Heitritter S, Moor Jr. F, Dluhy R, Sosa JA, Benn DE, Marsh DJ, Robinson BG, Schneider K, **Garber JE**, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SPA, Nose V, Li C, Stiles CD. A HIF1 regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PloS Genet 2005; 1:72-80.

84. Balmana J, Diez O, Campos B, Majewski M, Sanz J, Alonso C, Baiget M, **Garber JE**. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon? Breast Cancer Res Treat 2005; 92:273-7.

85. Rebbeck TR, Friebel T, Wagner T, Lynch HT, **Garber JE**, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after biolateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005 ; 23 :7804-10.

86. Larson PS, Schlechter BL, de las Morenas A, **Garber JE**, Cupples LA, Rosenberg CL. Allele imbalance or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 2005 ; 23 :8613-19.

87. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, **Garber JE,** Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2006; 64:496-504.

88. Colilla S, Kantoff PW, Neuhausen SL, Godwin AK, Daly MB, Narod SA, **Garber JE**, Lynch HT, Brown M, Weber BL, Rebbeck TR. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2006; 27:599-605.

89. Wong P, Verselis SJ, **Garber JE**, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 2006; 130:73-9.

90. DiGianni LS, Rue M, Emmons K, **Garber JE**. Complementary medicine use before and 1 year following genetic testing for BRCA 1/2 mutations. Cancer Epidemiol Biomarkers Prev 2006; 15:70-5.

91. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, **Garber JE**, Cramer DW, Crum CP. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30;230-6.

92. Patenaude AF, Dorval M, DiGianni LS, Schneider KA, Chittenden A, **Garber JE.** Sharing BRCA 1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 2006; 24:700-6.

93. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, **Garber JE**, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR. Mortality after bilateral salpingo-oophorectomy in BRCA 1 and BRCA 2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7:223-9.

94. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, **Garber JE**, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006; 8: R15.

95. Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, **Garber JE**, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA. Frequent met oncogene amplification in a BRC1/Trp53 mouse model of mammary tumorigenesis. Cancer Res 2006; 66:7:3452-5.

96. Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, **Garber JE**, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C. National Comprehensive Cancer Network. Breast cancer screening and diagnosis. J Natl Compr Canc Netw 2006; 5:480-508.

97. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, **Garber JE**, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24:2437- 43.

98. American Society of Clinical Oncology; Ganz P, Kwan L, Somerfield M, Alberts D, **Garber JE,** Offit K, Lippman SM. The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Onc 2006; 24:2948-57.

99. Burstein HJ, Mayer E, Partridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HP, Winter EP, **Garber JE**. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 2006; 7:158-61.

100. Golshan M, Miron A, Nixon AJ, **Garber JE**, Cash EP, Iglehart JD, Harris JR, Wong JS. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006; 192:58-62.

101. Abramson N, Costantino JP, **Garber JE,** Berliner N, Wickerham DL, Wolmark N. Effect of Factor V. Leiden and prothrombin G20210A mutations on thromboembolic risk in the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial. J Natl Cancer Inst 2006; 98:904-10.

102. Schneider K, Chittenden AB, Branda KJ, Keenan MA, Joffe S, Patenaude AF, Reynolds H, Dent K, Eubanks S, Goldman J, Leroy B, Warren NS, Taylor K, Vockley CW, **Garber JE**. Ethical issues in cancer genetics: I) whose information is it? J Genet Couns 2006; 15:491-503.

103. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Blouhshtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, **Garber JE,** Richardson AL, Schnitt SJ, Nikoslsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 1:259-73.

104. Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredricksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakbowska A, Lubinski J, Gronwald J, Spurdle AB; Confab K, Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, Andrulis IL, Ilyushik E, Glendon G, Devilee P, Vreeswijk MP, Vasen HF, Borg A, Backenhorn K, Struewing JP, Greene MH, Neuhausen SL, Rebbeck TR, Nathanson K, Domchek S, Wagner T, **Garber JE**, Szabo C, Zikan M, Foretova L, Olson JE, Sellers TA, Lindor N, Nevanlinna H, Tommiska J, Aittomaki K, Hamann U, Rashid MU, Torres D, Simard J, Durocher F, Guenard F, Lynch HT, Isaacs C, Weitzel J, Olopade OI, Narod S, Daly MB, Godwin AK, Tomlinson G, Easton DF, Chenevix-Trench G, Antoniou AC. Consortium of Investigators of Modifiers of BRCA1/2. AURKA F31 I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev 2007; 16:1416-21.

105. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, **Garber JE**, Feltmate CM, Berkowitz RS, Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25:3985-90.

106. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, **Garber JE,** Huntsman, D. Germline E-Cadherin mutations in familial lobular breast cancer. J Med Genet 2007; 44:726-31.

107. Javid SH, Carson, JW, **Garber JE**, Birdwell, RL, Lester S, Lipsitz S, Golshan M. Breast MRI wire-guided excisional biopsy: specimen size as compared to mammogram wire-guided excisional biopsy and implications for use. J Surg Oncol 2007; 14:3352-8.

108. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, **Garber JE**, Olopade OI, Marchand LL, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007; 121:2661-7.

109. Freibel M, Domchk SM, Newhausen SL, Wagner T, Evans DG, Isaacs C, **Garber JE**, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA 1 and BRCA 2 mutation carriers. Clin Breast Cancer 2007; 7:875-82.

110. Gao B, Xie XJ, Huang C, Shames DS, Chen TT, Lewis CM, Bian A, Zhang B, Olopade OI, **Garber JE**, Euhus DM, Tomlinson GE, Minna JD. RASSF1A polymorphism A133S associated with early onset breast cancer in BRCA ½ mutation carriers. Cancer Res 2008; 68:22-5.

111. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, **Garber JE**, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26:1331-7.

112. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, DiGianni L, Li FP, Fraumeni JF Jr, Syngal S, **Garber JE**. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 2008; 299:1315-9.

113. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, **Garber JE**, Muto MG, Tworoger S, Crum CP. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109:168-73.

114. Patenaude AF, Orozco S, Li X, Kaelin CM, Gadd M, Matory Y, Mayzel K, Roche CA, Smith BL, Farkas W, **Garber JE**. Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psycho-Oncology 2008; 17:831-43.

115. Keating NL, Stoeckert KA, Regan MM, Digianni L, **Garber JE.** Physicians' experiences with BRCA 1/2 testing in community settings. J Clin Oncol 2008; 26:5789-96.

116. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, **Garber JE**, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14:7871-7.

117. Collins LC, Martyniak AJ, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, **Garber JE**. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 2009; 33:1093-1097.

118. Peshkin BN, Demarco TA, **Garber JE**, Valdimarsdottir HB, Patenaude AF, Schneider KA, Schwartz MD, Tercyak KB. Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the pediatric BRCA1/2 testing attitudes scale (P-TAS). J Pediatr Psychol 2009; 34: 627-38.

119. Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G; kConFab, Singer CF, Pfeiler G, Neuhausen Sl, Lynch HT, **Garber JE**, Weitzel JN, Isaacs C, Couch F, Narod SA, Runbinstein WS, Tomlinson GE, Ganz PA, Olopade OI, Tung N, Blum JL, Greenberg R, Nathanson KL, Daly MB. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort BRCA ½ mutation carriers. Cancer Res. 2009; 69:5801-10.

120. Mueller J, Gazzoli, Bandipaliam P, **Garber J**, Syngal S, Kolodner RD. Comprehensive Molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolypos colorectal cancer) cases. Cancer Res.2009; 69:7053-61

121. De Nicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, Nathanson KL, Caligo MA, Vidal M, Cusick ME, **Garber JE**. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1. Cancer Res. 2009; 69:7030-7.

122. Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, **Garber JE**, Freedman ML, Henderson BE, Zou L, Shannon KM, Sgroi DC, Haber DA, Bell DW. Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator claspin. Mol Cancer Res. 2009; 7:1510-6

123. Folkins AK, Saleemuddin A, Garrett LA, **Garber JE**, Muto MG, Tworoger SS, Crum CP. Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecol Oncol. 2009; 15:108-11.

124. Ibarra-Drendall C, Wilke LG, Zalles C, Scott V, Archer LE, Lem S, Yee LD, Lester J, Kulkarni S, Murekeyisoni C, Wood M, Wilson K, **Garber J**, Gentry C, Stouder A, Broadwater G, Baker JC Jr, Vasilatos SN, Owens E, Rabiner S, Barron AC, Seewaldt VL. Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB cross-sectional study). Cancer Epidemiology Biomarkers Prev. 2009; 18:1379-85.

125. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, **Garber J**E, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan;119(1):137-44.

126. Ruddy KJ, Gelber S, Shin J, **Garber JE**, Rosenberg R, Przypysny M, Partridge AH Genetic testing in young women with breast cancer: results from a Web-based survey. Ann Oncol. 2010; 21:74107.

127. Ozanne EM, Wittenberg E, **Garber JE**, Weeks JC. Breast Cancer prevention: patient decision making and risk communication in the high risk setting. Breast J. 2010; 16:38-47.

128. Demarco TA, Nusbaum RH, Peshkin BN, Patenaude AF, Schneider KA, **Garber JE,** Valdimarsdottir HB, Tercyak KP. Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together. Patient Educ Couns. 2010; 78:29-33.

129. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010; 12: R95.

130. Domchek SM, Friebel TM, **Garber JE**, Isaacs C, Matloff E, Eales R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB Weitzel J, Ganz PA, Pichert G, Olopade OI, Tomlinson G, Tung N, Blum JL, Couch F, Rebbeck TR. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA ½ mutation carriers. Breast Cancer Res Treat. 2010; 124:129-203.

131. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong, C, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, **Garber JE**. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Onc. 2010; 28:1145-53.

132. **Garber JE**, Halabi S, Tolaney S, Kaplan E, Archer L, Atkins J, Edge S, Shapiro Dressler L, Paskett E, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Rotche R, Shahab N, Berliner N, Cancer and Leukemia Group P. Factor V Leiden mutation and the risk of thromboembolic events in women receiving adjuvant tamoxifen for breast Cancer. J Natl Cancer Inst. 2010; 7:102:942-9.

133. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, **Garber JE**, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN. Genetic/Familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010; 8:562-94.

134. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, **Garber JE**, Merajver SD, Balmana J, Meirovitz A, Domchek SM. Breast Cancer Res Treat. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010; 121:389-98.

135. Tutt A, Robson M, **Garber JE**, Domcheck SM, Aude MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet. 2010; 376:235-244.

136. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs G, **Garber JE**, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304:967-75.

137. Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szasz AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, **Garber JE**, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1 associated breast cancers. Breast Cancer Res. 2010; 12: R95.

138. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, **Garber JE,** Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Mesoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. J Natl Compre Canc Netw. 2010; 8:1112-46.

139. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F: Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, **Garber JE,** Visvanathan K, Griffin CA,

Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010; 124:441-51.

140. Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD, Schnitt SJ, Collins LC, **Garber JE.** Clinical outcome of triple negative breast cancer in BRCA 1 mutation carriers and noncarriers. Clin Cancer Res. 2010; 16:5796-804.

141. DeNicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domcheck SM, Nathanson, KL, Caligo, MA, Vidal M, Cusick ME, **Garber JE**. Multimodel Assessment of protein functional deficiency supports pathogenicity of BRCA1. Cancer Res. 2010; 69: 7030-7037.

142. Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD, Schnitt SJ, Collins LC, Weaver DT, **Garber JE**. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res. 2010; 16:5796-804.

143. Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, **Garber JE**, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res. 2010; 12: R95.

144. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, **Garber JE**, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304:967-75.

145. Golshan M, **Garber JE**, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011; 18:733-7.

146. Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan P, Olopade OI, Domcheck SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P; KConFab, Moore R, Southey MC, Hopper JL, **Garber JE**, Huntsman DG. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011:48:64-8.

147. Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, **Garber JE**, Tung N. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 2011; 117:3093-100

148. Levy DE, Byfield SD, Comstock CG, **Garber JE**, Syngal S, Crown WH, Shields AE. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011; 13:349-55.

149. Goss PE, Ingle JN, Ales-Matinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, **Garber JE**, Fabian CJ, Puhol P, Maunsell E, Farmer P, Gelmon, KA, Tu D, Richardson, H; the NCIC CTG MAP.3 Study Investigators. Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med. 2011; 3364:2381-91.

150. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI, Riegert-Johnson D, Foretova, L, Silva EM, Digianni L, Verselis SJ, Schneider K, Li FP, Fraumeni J, **Garber JE**, Syngal S. Gastric cancer in individuals with Li-Fraumeni syndrome. Gent Med. 2011; 13:651-7.

151. Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Sinerg CF, Pfeiler G, Lynch HT, **Garber JE,** Cuch F, Weitzel JN, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev. 2011; 20:1690-702.

152. Rebbeck TR, Mitra N, Domcheck SM, Wan F, Friebel TM, Tran TV, Singer CF, Tea MK, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder CL, **Garber JE**, Antoniou AC, Peock S, Evans DG, Paterson J, Kennedy MJ, Donaldson A, Dorkins H, Easton DF: for the Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE), Rubinstein WS, Daly MB, Isaacs C, Nevanlinna H, Couch FJ, Andrulis IL, Freidman E, Laitman Y, Ganz PA, Tomlinson GE, Neuhausen SL, Narod SA, Phelan CM, Greenberg R, Nathanson KL. Modification of BRCA1-associated breast and ovarian cancer risk by BRCA1-interacting genes. Cancer Res. 2011; 71:5792-5805.

153. Domcheck SM, Mitchell G, Lindeman GJ, Tung NM, Balmana J, Isakoff SJ, Schmutzler R, Audeh MW, Loman N, Scott C, Friedklander M, Kaufman B, **Garber JE,** Tutt A. Robson ME. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated Breast Cancer. J Clin Oncol. 2011; 10:29:4224-6.

154. Dewanwala A, Chittenden A, Rosenblatt M, Mercado R, **Garber JE**, Syngal S, Stoffel EM. Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome. Fam Cancer. 2011; 10:549-56.

155. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C,McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B,Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB;

HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, **Garber JE**, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012; 21:134-47.

156. Sharff ME, DeMarco TA, Mays D, Peshkin BN, Valdimarsdottir HB, **Garber JE**, Schneider KA, Patenaude AF, Tercyak KP. Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children. Genet Test Mol Biomarkers. 2012; 16:376-82.

157. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, **Garber JE**, Stearns V. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat. 2012; 131:915-24.

158. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, Telli M, Pochebit, SM, Lypas G, **Garber JE**. Breast cancer phenotype in women with TP53 germline mutations: A Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012; 133:1125-30.

159. Liu J, Cristea MC Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, **Garber JE**, Weitzel JN. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012; 205:35-41.

160. Finkelman BS, Rubinstein WS, Friedman S, Friebel TM Dubitsky S, Shonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, **Garber JE,** Schildkraut J, Daly MB, Isaacs C, Pichert G, Newhausen SL, Couch FJ, Van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012; 30:1321-8.

161. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q. Tian R, Bowman-Colin C. Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, **Garber JE,** Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging Agents. Cancer Discovery 2012; 2:366-75.

162. Martins FC, De S, Aimendro V, Gonen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, **Garber JE**, Fetten K, Michor F, Polyak K. Evolutionary Pathways in BRCA1-Associated Breast Tumors. Cancer Discovery. 2012; 2:503-511.

163. Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, Polubriaginof F, Parmigiani G, **Garber JE**, Smith BL, Gadd MA, Specht MC, Guidi AJ, Roche CA, Hughes KS. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012; 136:627-33.

164. Patenaude AF, Demarco TA, Peshkin BN, Valdimarsdottir H, **Garber JE**, Schneider KA, Hewitt L, Hamilton J, Tercyak KP. Talking to Children About Maternal BRCA1/2 Genetic Test Results: A Qualitative Study of Parental Perceptions and Advice. J Genet Couns. 2012; 22:303-14.

165. Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, **Garber JE**, Syngal S, Stoffel EM. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012; 127:544-51.

166. Mai PL, Malkin D, **Garber JE**, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF Jr, Savage SA. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012; 205:479-87.

167. Buckley JM, Coopey SB, Sharko J, Polubriaginof F, Drohan B, Belli AK, Kim EM, Garber **JE**, Smith BL, Gadd MA, Specht MC, Roche CA, Gudewicz TM, Hughes KS. The feasibility of using natural language processing to extract clinical information from breast pathology reports. J Pathol Inform. 2012; 3:23.

168. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B; SWE-BRCA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U; HEBON, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB; EMBRACE, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson

R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H; GEMO Study Collaborators, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J; KConFab Investigators, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, **Garber JE**, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012; 21:1362-70.

169. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachaqui M, Ping S, Narod SA; Hereditary Breast Cancer Study Group. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012 Dec 4;107(12):2005-9. doi: 10.1038/bjc.2012.483. Epub 2012 Oct 25.

170. Kaplan JS, Schnitt SJ, Collins LC, Wang Y, **Garber JE**, Montgomery K, West RB, Krag K, Fetten K, Lincoln A, Tung NM. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers. Am J Surg Pathol. 2012; 36:1483-8.

171. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, Stephens PJ, McLaren S, Butler AP, Teague JW, Jönsson G, **Garber JE**, Silver D, Miron P, Fatima A, Boyault S, Langerød A, Tutt A, Martens JW, Aparicio SA, Borg Å, Salomon AV, Thomas G, Børresen-Dale AL, Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR; Breast Cancer Working Group of the International Cancer Genome Consortium. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149:979-93.

172. Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, **Garber JE**, Syngal S, Stoffel EM.

Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012; 127:544-51. PMID: 22940489

173. Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, **Garber JE.** Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary cancer and how much do they worry? Psychooncology. 2013; 22:2024-31.

174. Tercyak KP, Mays D, DeMarco TA, Peshkin BN, Valdimarsdottir HB, Schneider KA, **Garber JE**, Patenaude AF. Decisional outcomes of maternal disclosure of BRCA 1/2 genetic test results to children. Cancer Epidemiol Biomarkers Prev. 2013; 22;1260-6.

175. Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, **Garber JE**. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013; 139:193-198.

176. Mays D, Demarco TA, Luta G, Peshkin BN, Patenaude AF, Schneider KA, **Garber JE**, Tercyak KP. Distress and the Parenting Dynamic Among BRCA 1/2 Tested Mothers and Their Partners. Health Psychol. 2013;

177. Conner JR, Meserve E, Pizer E, **Garber JE**, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2013.

178. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, Neuhausen SL, Kim-Sing C, Tung N, Karlan B, Foulkes WD, Sun P, Narod S; Hereditary Breast Cancer Study Group. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013 May;99(6):1724-8. Epub 2013 Feb 13.

179. Ng AK, **Garber JE**, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013 Jun 20;31(18):2282-8. Epub 2013 Apr 22.

180. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013 Jul;130(1):127-31. Epub 2013 Apr 3.

181. Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M, Clark J, Herlihy W, Lin SJ, Chew G,

Thompson EW, Greene-Colozzi A, Richardson AL, Rosson GD, Pike M, **Garber JE**, Nikolsky Y, Blum JL, Au A, Hwang ES, Tamimi RM, Michor F, Haviv I, Liu XS, Sukumar S, Polyak K. Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 2013 Jul 3;13(1):117-30. Epub 2013 Jun 13.

182. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachaqui M, Chornokur G, Ping S, Narod SA; Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014 Jan 21;110(2):530-4. Epub 2013 Nov 28.

183. Vassy JL, Lautenbach DM, McLaughlin HM, Kong SW, Christensen KD, Krier J, Kohane IS, Feuerman LZ, Blumenthal-Barby J, Roberts JS, Lehmann LS, Ho CY, Ubel PA, MacRae CA, Seidman CE, Murray MF, McGuire AL, Rehm HL, Green RC; MedSeq Project. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials. 2014 Mar 20; 15:85.

184. Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, **Garber JE**, McCormicks S, Kinney AY, Luta G, Kelleher S, Leventhal KG, Vegella P, Tong A, King L. Randomized Noninferiority Trial of Telephone Versus In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer. J Clin Oncol. 2014 Mar 1;32(7):618-26. Epub 2014 Jan 21.

185. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, **Garber JE**, Kaklamani VG; Northwestern Cancer Genetics Group. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15;120(10):1557-64. Epub 2014 Feb 12.

186. Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, **Garber JE**. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Res Treat. 2014 Jul;146(1):175-82.

187. Mays D, DeMarco TA, Luta G, Peshkin BN, Patenaude AF, Schneider KA, **Garber JE**, Tercyak KP. Distress and the parenting dynamic among BRCA1/2 tested mothers and their partners. Health Psychol. 2014 Aug;33(8):765-73. Epub 2013 Jun 24.

188. Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, **Garber JE**. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014 Aug;25(8):1656-63.

189. Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, **Garber JE**, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014 Nov;148(2):397-406. Epub 2014 Oct 14.

190. Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, **Garber JE**, Livingston DM. BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun. 2014 Nov 17; 5:5496.

191. O'Neill SC, Mays D, Patenaude AF, **Garber JE**, DeMarco TA, Peshkin BN, Schneider KA, Tercyak KP. Women's concerns about the emotional impact of awareness of heritable breast cancer risk and its implications for their children. J Community Genet. 2015 Jan;6(1):55-62. Epub 2014 Aug 7.

192. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, **Garber JE**, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015 Jan 1;121(1):25-33. Epub 2014 Sep 3.

193. Peterlongo P, Chang-Claude J, Moysich KB, et al, Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16. Epub 2014 Oct 21

194. Bober SL, Recklitis CJ, Bakan J, **Garber JE**, Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med. 2015 Jan;12(1):189-97. Epub 2014 Oct 14.

195. Alderfer MA, Zelley K, Lindell RB, Novokmet A, Mai PL, **Garber JE**, Nathan D, Scollon S, Chun NM, Patenaude AF, Ford JM, Plon SE, Schiffman JD, Diller LR, Savage SA, Malkin D, Ford CA, Nichols KE. Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. 2015 Jan 15;121(2):286-93. Epub 2014 Sep 15.

196. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, **Garber JE**, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy with Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10;33(17):1902-9. Epub 2015 Apr 6.

197. Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, **Garber JE**, Wilkins-Haug L, Vora NL, Warsof S, Goldberg J, Ziainia T, Halks-Miller M. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA. 2015 Jul 14;314(2):162-9.

198. McEvoy MP, Coopey SB, Mazzola E, Buckley J, Belli A, Polubriaginof F, Merrill AL, Tang R, **Garber JE**, Smith BL, Gadd MA, Specht MC, Guidi AJ, Roche CA, Hughes KS. Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma in Situ (LCIS). Ann Surg Oncol. 2015 Oct;22(10):3346-9. Epub 2015 Aug 5.

199. Yurgelun MB, Hiller E, **Garber JE**. Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing? J Clin Oncol. 2015 Oct 1;33(28):3092-5. Epub 2015 Aug 17.

200. Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, Hung RJ, Sellers TA, Witte JS, Pharoah P, Henderson BE, Gruber SB, Hunter DJ, **Garber JE**, Joshi AD, McDonnell K, Easton DF, Eeles R, Kote-Jarai Z, Muir K, Doherty JA, Schildkraut JM. A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):193-200. Epub 2015 Dec 4.

201. Ruddy KJ, Risendal BC, **Garber JE**, Partridge AH. Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics. J Clin Oncol. Epub 2015 Dec 28.

202. Kensler TW, Spira A, **Garber JE**, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM. Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila). 2016 Jan;9(1):2-10.

203. Borgquist S, Tamimi RM, Chen WY, **Garber JE**, Eliassen AH, Ahern TP. Statin Use and Breast Cancer Risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):201-6.

204. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, **Garber JE**, Fostira F, Fountzilas G, Pasini B, Giannini

G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 9;18(1):15.

205. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22;7(12):13587-98.

206. Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, **Garber JE**, Partridge AH. BRCA1 and BRCA2 Mutation Testing in Young Women with Breast Cancer. JAMA Oncol. 2016 Jun 1;2(6):730-6.

207. Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, **Garber JE**, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, Wood S, Garraway L, Joffe S. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016 Oct;18(10):1011-9.

208. Dunning AM, Michailidou K, Kuchenbaecker KB, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016 Feb 29.

209. Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP and **Garber JE**. Frequency of germline mutations in 25 cancer susceptibility genes. J Clin Oncol. 2016 May 1;34(13):1460-8. 2016 May 1;34(13):1460-8.

210. Ji Y, Rounds T, Crocker A, Sussman B, Hovey RC, Kingsley F, Muss HB, **Garber JE**, Wood ME. The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. Cancer Prev Res (Phila). 2016 May;9(5):379-84. -6207.CAPR-15-0300. 2016 May;9(5):379-84.

211. Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, Tung NM, Manoukian S, Phelan CM, Sun P, Narod SA; Hereditary Breast Cancer Research Group. The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: An International Prospective Cohort Study. Br J Cancer. 2016 May 10;114(10):1160-4.

212. Malkin D, **Garber JE**, Strong LC, Friend SH. CANCER. The cancer predisposition revolution. Science. 2016 May 27;352(6289):1052-3.

213. Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, **Garber JE**, Partridge AH. BRCA1 and BRCA2 Mutation Testing in Young Women with Breast Cancer. JAMA Oncol. 2016 Jun 1;2(6):730-6.

214. Peshkin BN, Kelly S, Nusbaum RH, Similuk M, DeMarco TA, Hooker GW, Valdimarsdottir HB, Forman AD, Joines JR, Davis C, McCormick SR, McKinnon W, Graves KD, Isaacs C, **Garber JE,** Wood M, Jandorf L, Schwartz MD. Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling. J Genet Couns. 2016 Jun;25(3):472-82.

215. Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, **Garber JE**, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women with BRCA Mutations. JAMA Oncol. 2016 Nov 1;2(11):1434-1440. PubMed PMID: 27367496

216. Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, **Garber JE**, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. PubMed PMID: 26957554.

217. Balmaña J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, Nathanson KL, **Garber JE**, Couch FJ, Offit K, Robson ME, Domchek SM. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol. 2016 Dec;34(34):4071-4078. PubMed PMID: 27621404.

218. Yala A, Barzilay R, Salama L, Griffin M, Sollender G, Bardia A, Lehman C, Buckley JM, Coopey SB, Polubriaginof F, **Garber JE**, Smith BL, Gadd MA, Specht MC, Gudewicz TM, Guidi AJ, Taghian A, Hughes KS. Using machine learning to parse breast pathology reports. Breast Cancer Res Treat. 2017 Jan;161(2):203-211. PubMed PMID: 27826755.

219. Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, **Garber JE**, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2017 Feb;13(4):307-320. PubMed PMID: 27739325.

220. Yala A, Barzilay R, Salama L, Griffin M, Sollender G, Bardia A, Lehman C, Buckley JM, Coopey SB, Polubriaginof F, **Garber JE**, Smith BL, Gadd MA, Specht MC,

Gudewicz TM, Guidi AJ, Taghian A, Hughes KS. Using machine learning to parse breast pathology reports. Breast Cancer Res Treat. 2017 Jan;161(2):203-211. Epub 2016 Nov 8.

221. Borgquist S, Giobbie-Hurder A, Ahern TP, **Garber JE**, Colleoni M, et al. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol. 2017 Apr 10;35(11):1179-1188. PubMed PMID: 28380313.

222. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, **Garber JE**, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 Apr 1;77(7):1510-1541. PubMed PMID: 28373404.

223. Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, **Garber JE**, Joffe S, Van Allen EM, Gray SW, Ja Nne PA, Garraway LA, Wagle N. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genet Med. 2017 Jul;19(7):787-795. PubMed PMID: 28125075.

224. Mazzola E, Coopey SB, Griffin M, Polubriaginof F, Buckley JM, Parmigiani G, **Garber JE**, Smith BL, Gadd MA, Specht MC, Guidi A, Hughes KS. Reassessing risk models for atypical hyperplasia: age may not matter. Breast Cancer Res Treat. 2017 Sep;165(2):285-291. PubMed PMID: 28589368.

225. Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, **Garber JE**, Schrag D, Kibel AS, Freedman ML. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15;123(18):3532-3539. PubMed PMID: 28608931.

226. Slavin TP, Maxwell KN, Lilyquist J, Vijai J, Neuhausen SL, Hart SN, Ravichandran V, Thomas T, Maria A, Villano D, Schrader KA, Moore R, Hu C, Wubbenhorst B, Wenz BM, D'Andrea K, Robson ME, Peterlongo P, Bonanni B, Ford JM, **Garber JE**, Domchek SM, Szabo C, Offit K, Nathanson KL, Weitzel JN, Couch FJ. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer. 2017;3:22. PubMed PMID: 28649662.

227. Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell C, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, **Garber JE**, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 Oct;7(10):1098-1115. PubMed PMID: 28652380.

228. Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, **Garber JE**, Dominici LS. Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers. Am J Surg. 2017 Oct;214(4):687-694. PubMed PMID: 28683895.

229. Rosenberg SM, Ligibel JA, Meyerhardt JA, Jacobsen ED, **Garber JE**, Nekhlyudov L, Bunnell CA, Nutting P, Sprunck-Harrild K, Walsh SK, Partridge AH. Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study. J Cancer Educ. 2017 Oct 20; PubMed PMID: 29052110.

230. Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, **Garber JE**, Paweletz CP, Oxnard GR. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res. 2017 Dec 1;23(23):7351-7359. PubMed PMID: 28947568.

231. Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, **Garber JE**, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017 Dec 1;3(12):1634-1639. PubMed PMID: 28772291.

232. Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, **Garber JE**, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2018 Jan 1;29(1):154-161. PubMed PMID: 29045554.

233. O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, **Garber JE**, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb;65(2) PubMed PMID: 29077256.

234. Gucalp A, Zhou XK, Cook ED, **Garber JE**, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ. A Randomized Multicenter Phase II Study of

Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. PubMed PMID: 29453232.

235. Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, **Garber JE**, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers. Ann Oncol. 2018 Apr 1;29(4):903-909. PubMed PMID: 29452344.

236. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, **Garber J**, Gauthier-Villars M, Gehrig A, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, Peruga N, Peterlongo P, Pohl E, Pradhan N, Prajzendanc K, Prieur F, Pujol P, Radice P, Ramus SJ, Rantala J, Rashid MU, Rhiem K, Robson M, Rodriguez GC, Rogers MT, Rudaitis V, Schmidt AY, Schmutzler RK, Senter L, Shah PD, Sharma P, Side LE, Simard J, Singer CF, Skytte AB, Slavin TP, Snape K, Sobol H, Southey M, Steele L, Steinemann D, Sukiennicki G, Sutter C, Szabo CI, Tan YY, Teixeira MR, Terry MB, Teulé A, Thomas A, Thull DL, Tischkowitz M, Tognazzo S, Toland AE, Topka S, Trainer AH, Tung N, van Asperen CJ, van der Hout AH, van der Kolk LE, van der Luijt RB, Van Heetvelde M, Varesco L, Varon-Mateeva R, Vega A, Villarreal-Garza C, von Wachenfeldt A, Walker L, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Yoon SY, Zanzottera C, Zidan J, Zorn KK, Hutten Selkirk CG, Hulick PJ, Chenevix-Trench G, Spurdle AB, Antoniou AC, Nathanson KL.

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12. PubMed PMID: 29446198

237. Borgquist S, Hall P, Lipkus I, **Garber JE**. Towards Prevention of Breast Cancer: What Are the Clinical Challenges?. Cancer Prev Res (Phila). 2018 Apr 16; PubMed PMID: 29661853.

238. Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip JM, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, **Garber JE**, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. Cancer Res. 2018 Mar 20; PubMed PMID: 29559475.

239. Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, Kraft P, Laden F, Mucci L, Parmigiani G, Schrag D, Syngal S, Tamimi RM, Viswanath K, Yurgelun MB, **Garber JE**. Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discov. 2018 Jul;8(7):803-811. doi: 10.1158/2159-8290.CD-17-1415. Epub 2018 Jun 15. PubMed PMID: 29907587.

240. Tung NM, **Garber JE**. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5. Review. PubMed PMID: 29867226; PubMed Central PMCID: PMC6048046.

241. Rana HQ, Cochrane SR, Hiller E, Akindele RN, Nibecker CM, Svoboda LA, Cronin AM, Shimelis, Lathan CS. A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings. J Community Genet. 2018 Jul;9(3):233-241. doi: 10.1007/s12687-017-0347-z. Epub 2017 Nov 18. PubMed PMID: 29151150;

242. Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Godwin AK, Konstantopoulou I, Nevanlinna H, Sharma P, Yannoukakos D, Yao S, Feng BJ, Tippin Davis B, Lilyquist J, Pesaran T, Goldgar DE, Polley EC, Dolinsky JS, Couch FJ. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst. 2018 Aug 1;110(8):855-862. doi: 10.1093/jnci/djy106. PubMed PMID: 30099541.

243. Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, Speare V, Dolinsky JS, Chao EC, Garber JE. Differences in TP53 Mutation Carrier Phenotypes

Emerge From Panel-Based Testing. J Natl Cancer Inst. 2018 Aug 1;110(8):863-870. doi: 10.1093/jnci/djy001. PubMed PMID: 29529297.

244. Pathania S, **Garber JE**. Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers?. J Natl Cancer Inst. 2018 Sep 1;110(9):925-926. doi: 10.1093/jnci/djy047. PubMed PMID: 29767746.

245. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjorge L, Brenton J, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Claes KBM, Couch FJ, Cramer DW, Daly MB, deFazio A, Dennis J, Diez O, Domchek SM, Dörk T, Easton DF, Eccles DM, Fasching PA, Fortner RT, Fountzilas G, Friedman E, Ganz PA, **Garber J**, Giles GG, Godwin AK, Goldgar DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT, Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L, McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM, Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA, Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W, Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE, Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A, Vega A, Edwards DV, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 Sep 15;78(18):5419-5430. Epub 2018 Jul 27. PubMed PMID: 30054336

246. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, **Garber J**, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 1;29(10):2153. PubMed PMID: 29733336.

247. Katona BW, Yurgelun MB, **Garber JE**, Offit K, Domchek SM, Robson ME, Stadler ZK. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med. 2018 Nov;20(11):1324-1327. doi: 10.1038/gim.2018.12. Epub 2018 Mar 1. PubMed PMID: 29493579.

248. Cruz C, Llop-Guevara A, **Garber JE**, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. PubMed PMID: 30240327

249. Weiss A, **Garber JE**, King T. Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes. JAMA Surg. 2018 Dec 1;153(12):1145-1146. doi: 10.1001/jamasurg.2018.2493. PubMed PMID: 30167656.

250. Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin A, Couch FJ, Craft B, Currie R, Dlott CC, Dolman L, den Dunnen JT, Dyke SOM, Domchek SM, Easton D, Fischmann Z, Foulkes WD, **Garber J**, Goldgar D, Goldman MJ, Goodhand P, Harrison S, Haussler D, Kato K, Knoppers B, Markello C, Nussbaum R, Offit K, Plon SE, Rashbass J, Rehm HL, Robson M, Rubinstein WS, Stoppa-Lyonnet D, Tavtigian S, Thorogood A, Zhang C, Zimmermann M, Burn J, Chanock S, Rätsch G, Spurdle AB. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018 Dec;14(12):e1007752. doi: 10.1371/journal.pgen.1007752. eCollection 2018 Dec. PubMed PMID: 30586411

251. Punglia RS, Bifolck K, Golshan M, Lehman C, Collins L, Polyak K, Mittendorf E, **Garber J**, Hwang SE, Schnitt SJ, Partridge AH, King TA. Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov;2(4):pky063. doi: 10.1093/jncics/pky063. Epub 2018 Dec 27. PubMed PMID: 30627695

252. Acevedo F, Armengol VD, Deng Z, Tang R, Coopey SB, Braun D, Yala A, Barzilay R, Li C, Colwell A, Guidi A, Cetrulo CL Jr, **Garber J**, Smith BL, King T, Hughes KS. Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions. Breast Cancer Res Treat. 2019 Jan;173(1):201-207. doi: 10.1007/s10549-018-4962-0. Epub 2018 Sep 20. PubMed PMID: 30238276.

253. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI,

Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, **Garber J**, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubiński J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Jan 25;10(1):431. doi: 10.1038/s41467-018-08054-4. PubMed PMID: 30683880

254. Rosenberg SM, Ligibel JA, Meyerhardt JA, Jacobsen ED, **Garber JE**, Nekhlyudov L, Bunnell CA, Nutting P, Sprunck-Harrild K, Walsh SK, Partridge AH. Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study. J Cancer Educ. 2019 Apr;34(2):229-233. doi: 10.1007/s13187-017-1291-7. PubMed PMID: 29052110; PubMed Central PMCID: PMC5910291.

255. Gucalp A, Zhou XK, Cook ED, **Garber JE**, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ. A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. PubMed PMID: 29453232.

256. Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, **Garber JE**, Overmoyer BA. Prevalence of germline variants in inflammatory breast cancer. Cancer. 2019 Apr 1;. doi: 10.1002/cncr.32062. [Epub ahead of print] PubMed PMID: 30933323.

257. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, Ausems MGEM, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, **Garber J**, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo Á, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong KR, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B, Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriguez GC, Schmutzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Tucker KM, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yannoukakos D, Greene MH, Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade OI, Rebbeck TR, Huo D. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 Apr 1;111(4):350-364. doi: 10.1093/jnci/djy132. PubMed PMID: 30312457

258. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A, Brauch H, Brenner H, Broeks A, Burwinkel B, Caldés T, Caligo MA, Campa D, Campbell I, Canzian F, Carter J, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, Dennis J, Devilee P, Diez O, Dörk T, Dunning AM, Dwek M, Eccles DM, Ejlertsen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Friedman E, Frost D, Gabrielson M, Gago-Dominguez M, Ganz PA, Gapstur SM, **Garber J**, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hoover RN, Hopper JL, Hulick PJ, Humphreys K, Imyanitov EN, Isaacs C, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Karlan BY, Khusnutdinova E, Kiiski JI, Ko YD, Jones ME, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leslie G, Lester J, Lesueur F, Lindström S, Long J, Loud JT, Lubiński J, Makalic E, Mannermaa A, Manoochehri M, Margolin S, Maurer T, Mavroudis D, McGuffog L, Meindl A, Menon U, Michailidou K, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Pharoah PDP, Plaseska-Karanfilska D, Poppe B, Presneau N, Radice P, Rantala J, Rennert G, Risch HA, Saloustros E, Sanden K, Sawyer EJ, Schmidt MK, Schmutzler RK, Sharma P, Shu XO, Simard J, Singer CF, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Torres D, Truong T, Tung N, Vachon CM, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Wang Q, Wappenschmidt B, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Kraft P, Antoniou AC, Zheng W, Easton DF, Milne RL, Beesley J, Chenevix-Trench G. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nat Commun. 2019 Apr 15;10(1):1741. doi: 10.1038/s41467-018-08053-5. PubMed PMID: 30988301

259. Weiss A, Grossmith S, Cutts D, Mikami SA, Suskin JA, Graichen MK, Rojas NA, Pace LE, Joyce E, Rhei E, Scheib R, Bychkovsky B, **Garber JE**, Morganstern D, King TA. Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Res Treat. 2019 May;175(1):229-237. doi: 10.1007/s10549-018-05116-5. Epub 2019 Jan 21. PubMed PMID: 30666540.

260. Rana HQ, Clifford J, Hoang L, LaDuca H, Helen Black M, Li S, McGoldrick K, Speare V, Dolinsky JS, Gau CL, **Garber JE**. Genotype-phenotype associations among panel-based TP53+ subjects. Genet Med. 2019 May 20;. doi: 10.1038/s41436-019-0541-y. [Epub ahead of print] PubMed PMID: 31105275.

261. Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, Foulkes WD, Ganz PA, **Garber J**, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, Lu KH, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN, Collaborators GS, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019 May 21;. doi: 10.1002/humu.23804. [Epub ahead of print] PubMed PMID: 31112363.

262. Sacca RE, Koeller DR, Rana HQ, **Garber JE**, Morganstern DE. Trans-counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants. J Genet Couns. 2019 Jun;28(3):708-716. doi: 10.1002/jgc4.1046. Epub 2019 Jan 24. PubMed PMID: 30680866.

263. Chi D, Singhal H, Li L, Xiao T, Liu W, Pun M, Jeselsohn R, He H, Lim E, Vadhi R, Rao P, Long H, **Garber J**, Brown M. Estrogen receptor signaling is reprogrammed during breast tumorigenesis. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11437-11443. doi: 10.1073/pnas.1819155116. Epub 2019 May 20. PubMed PMID: 31110002

264. Wood ME, **Garber JE**, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 Jul;25(4):575-577. doi: 10.1111/tbj.13292. PubMed PMID: 31280501.

265. Dayan E, Chittenden A, **Garber JE**, Wo L, Caterson SA, Carty MJ, Erdmann-Sager J. Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction. Plast Reconstr Surg. 2019 Jul;144(1):12-20. doi: 10.1097/PRS.0000000000005693. PubMed PMID: 31246791.

266. Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, **Garber J**, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF,

Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D, Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 Jul;121(2):180-192. doi: 10.1038/s41416-019-0492-8. Epub 2019 Jun 19. PubMed PMID: 31213659.

267. Tang R, Acevedo F, Lanahan C, Coopey SB, Yala A, Barzilay R, Li C, Colwell A, Guidi AJ, Cetrulo C**, Garber J**, Smith BL, Gadd MA, Specht MC, Hughes KS. Incidental breast carcinoma: incidence, management, and outcomes in 4804 bilateral reduction mammoplasties. Breast Cancer Res Treat. 2019 Jul 17;. doi: 10.1007/s10549-019-05335-4. [Epub ahead of print] PubMed PMID: 31317348.

268. Underhill-Blazey M, Stopfer J, Chittenden A, Nayak MM, Lansang K, Lederman R, **Garber J**, Gundersen DA. Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing. Patient Educ Couns. 2019 Aug;102(8):1558-1564. doi: 10.1016/j.pec.2019.04.014. Epub 2019 Apr 13. PubMed PMID: 31010603.

269. Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, **Garber JE,** Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019 Nov 20;37(33):3152-3165. doi: 10.1200/JCO.19.01472. Epub 2019 Sep 3. PubMed PMID: 31479306.

270. Song Y, Barry WT, Seah DS, Tung NM, **Garber JE,** Lin NU. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer. 2020 Jan 15;126(2):271-280. doi: 10.1002/cncr.32540. Epub 2019 Oct 3. PubMed PMID: 31581314; PubMed Central PMCID: PMC7003745.

271. Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, **Garber JE.** TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 Feb 25;:JCO1903292. doi: 10.1200/JCO.19.03292. [Epub ahead of print] PubMed PMID: 32097092

272. Mai PL, Sand SR, Saha N, Oberti M, Dolafi T, DiGianni L, Root EJ, Kong X, Bremer RC, Santiago KM, Bojadzieva J, Barley D, Novokmet A, Ketchum KA, Nguyen N, Jacob S, Nichols KE, Kratz CP, Schiffman JD, Evans G, Achatz MI, Strong LC, **Garber JE,** Ladwa SA, Malkin D, Weitzel JN. Li-Fraumeni Exploration Consortium Data Coordinating Center: A web-based resource for collaborative epidemiologic research on a rare cancer syndrome. Cancer Epidemiol Biomarkers Prev. 2020 Mar 10;. doi:

10.1158/1055-9965.EPI-19-1113. [Epub ahead of print] PubMed PMID: 32156722; NIHMSID:NIHMS1574768.

273. Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, **Garber JE**, Rana HQ, Sonpavde G. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med. 2020 Apr;22(4):709-718. doi: 10.1038/s41436-019-0720-x. Epub 2019 Dec 17. PubMed PMID: 31844177; PubMed Central PMCID: PMC7118025.

274. Mai PL, Sand SR, Saha N, Oberti M, Dolafi T, DiGianni L, Root EJ, Kong X, Bremer RC, Santiago KM, Bojadzieva J, Barley D, Novokmet A, Ketchum KA, Nguyen N, Jacob S, Nichols KE, Kratz CP, Schiffman JD, Evans DG, Achatz MI, Strong LC, **Garber JE,** Ladwa SA, Malkin D, Weitzel JN. Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):927-935. doi: 10.1158/1055-9965.EPI-19-1113. Epub 2020 Mar 10. PMID: 32156722

275. Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, **Garber JE.** TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 May 10;38(14):1539-1548. doi: 10.1200/JCO.19.03292. Epub 2020 Feb 25. PMID: 32097092

276. Kotsopoulos J, McGee EE, Lozano-Esparza S, **Garber JE,** Ligibel J, Collins LC, Polyak K, Brown M, Narod S, Tamimi RM, Eliassen AH. Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II. Cancer Epidemiol Biomarkers Prev. 2020 Jun;29(6):1264-1270. doi: 10.1158/1055-9965.EPI-19-1154. Epub 2020 Apr 10. PMID: 32277005

277. Duan H, Mansour S, Reed R, Gillis MK, Parent B, Liu B, Sztupinszki Z, Birkbak N, Szallasi Z, Elia AEH, **Garber JE,** Pathania S. E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells. J Cell Biol. 2020 Jun 1;219(6):e201908192. doi: 10.1083/jcb.201908192. PMID: 32391871

278. Patel JM, Goss A, **Garber JE,** Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Tung N. Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer. 2020 Jun 5;6:19. doi: 10.1038/s41523-020-0160-4. eCollection 2020. PMID: 32550264

279. Fabian CJ, Khan SA, **Garber JE,** Dooley WC, Yee LD, Klemp JR, Nydegger JL, Powers KR, Kreutzjans AL, Zalles CM, Metheny T, Phillips TA, Hu J, Koestler DC, Chalise P,

Yellapu NK, Jernigan C, Petroff BK, Hursting SD, Kimler BF. Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer. Cancer Prev Res (Phila). 2020 Jul;13(7):623-634. doi: 10.1158/1940-6207.CAPR-20-0050. Epub 2020 Apr 20. PMID: 32312713

280. Gao F, Pan X, Dodd-Eaton EB, Recio CV, Montierth MD, Bojadzieva J, Mai PL, Zelley K, Johnson VE, Braun D, Nichols KE, **Garber JE,** Savage SA, Strong LC, Wang W. A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome. Genome Res. 2020 Aug;30(8):1170-1180. doi: 10.1101/gr.249599.119. Epub 2020 Aug 18. PMID: 32817165

281. Maxwell KN, Wenz BM, Kulkarni A, Wubbenhorst B, D'Andrea K, Weathers B, Goodman N, Vijai J, Lilyquist J, Hart SN, Slavin TP, Schrader KA, Ravichandran V, Thomas T, Hu C, Robson ME, Peterlongo P, Bonanni B, Ford JM, **Garber JE,** Neuhausen SL, Shah PD, Bradbury AR, DeMichele AM, Offit K, Weitzel JN, Couch FJ, Domchek SM, Nathanson KL. Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precis Oncol. 2020 Aug 19;4:PO.19.00301. doi: 10.1200/PO.19.00301. eCollection 2020. PMID: 32954205

282. Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, McGoldrick K, **Garber JE,** Savage SA, Khincha PP, Gareth Evans D, Achatz MI, Nichols KE, Maxwell KN, Schiffman JD, Sandoval R; Li-Fraumeni Exploration (LIFE) Consortium, James PA, Spurdle AB. Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines. Hum Mutat. 2020 Sep;41(9):1555-1562. doi: 10.1002/humu.24060. Epub 2020 Jun 12. PMID: 32485079

283. Powers J, Pinto EM, Barnoud T, Leung JC, Martynyuk T, Kossenkov AV, Philips AH, Desai H, Hausler R, Kelly G, Le AN, Li MM, MacFarland SP, Pyle LC, Zelley K, Nathanson KL, Domchek SM, Slavin TP, Weitzel JN, Stopfer JE, **Garber JE,** Joseph V, Offit K, Dolinsky JS, Gutierrez S, McGoldrick K, Couch FJ, Levin B, Edelman MC, Levy CF, Spunt SL, Kriwacki RW, Zambetti GP, Ribeiro RC, Murphy ME, Maxwell KN. A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Res. 2020 Sep 1;80(17):3732-3744. doi: 10.1158/0008-5472.CAN-20-1390. Epub 2020 Jul 16. PMID: 32675277

284. Cole AP, **Garber JE**, Baniak N, Hirsch MS, Lee Chang S, Kibel AS. 'Case of the Month' from Brigham and Women's Hospital, Boston, MA, USA: a 70-year-old man with lung cysts and bilateral renal masses. BJU Int. 2020 Oct;126(4):428-432. doi: 10.1111/bju.15234. PMID: 33025754

285. Koeller DR, Schwartz A, Manning DK, Dong F, Lindeman NI, **Garber JE,** Ghazani AA. Novel Pathogenic Germline Variant of the Adenomatous Polyposis Coli (APC) Gene, p.S2627Gfs*12 Identified in a Mild Phenotype of APC-Associated Polyposis: A Case Report. Am J Case Rep. 2020 Dec 11;21:e927293. doi: 10.12659/AJCR.927293. PMID: 33303731

286. Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, **Garber JE.** TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29. PMID: 33119476

287. Ghazani AA, Breen KM, Dwan M, Barletta JA, Vatnick DR, Stokes SM, Block C, Doherty GM, Cohn AY, Marqusee E, **Garber JE,** Rana HQ. Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. Am J Case Rep. 2020 Dec 27;21:e927415. doi: 10.12659/AJCR.927415. PMID: 33361738

288. Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, **Garber JE,** Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 Jan;2(1):66-82. doi: 10.1038/s43018-020-00148-7. Epub 2020 Dec 14. PMID: 33738458

289. Rana HQ, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes SM, Fekrmandi F, Vatnick D, Matulonis UA, **Garber JE,** Wright AA. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol. 2021 Feb;160(2):457-463. doi: 10.1016/j.ygyno.2020.11.003. Epub 2020 Nov 21. PMID: 33229043

290. Bhatia S, Palomares MR, Hageman L, Chen Y, Landier W, Smith K, Umphrey H, Reich CA, Zamora KW, Armenian SH, Bevers TB, Blaes A, Henderson T, Hodgson D, Hudson MM, Korde LA, Melin SA, Merajver SD, Overholser L, Pruthi S, Wong FL, **Garber JE.** A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clin Cancer Res. 2021 Feb 15;27(4):967-974. doi: 10.1158/1078-0432.CCR-20-3609. Epub 2020 Dec 3. PMID: 33272980

291. Kuba MG, Lester SC, Bowman T, Stokes SM, Taneja KL, **Garber JE**, Dillon DA. Histopathologic features of breast cancer in Li-Fraumeni syndrome. Mod Pathol. 2021 Mar;34(3):542-548. doi: 10.1038/s41379-020-0610-4. Epub 2020 Jul 7. PMID: 32636452

292. Abou Alaiwi S, Nassar AH, Adib E, Groha SM, Akl EW, McGregor BA, Esplin ED, Yang S, Hatchell K, Fusaro V, Nielsen S, Kwiatkowski DJ, Sonpavde GP, Pomerantz M, **Garber JE,** Freedman ML, Rana HQ, Gusev A, Choueiri TK. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 Mar 30;34(13):108926. doi: 10.1016/j.celrep.2021.108926. PMID: 33789101

293. Tutt ANJ, **Garber JE,** Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. PMID: 34081848

294. Pace LE, Tung N, Lee YS, Hamilton JG, Gabriel C, Revette A, Raja S, Jenkins C, Braswell A, Morgan K, Levin J, Block J, Domchek SM, Nathanson K, Symecko H, Spielman K, Karlan B, Kamara D, Lester J, Offit K, **Garber JE,** Keating NL. Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. J Gen Intern Med. 2021 Jun 25. doi: 10.1007/s11606-021-06970-8. Online ahead of print. PMID: 34173196

295. Wood ME, Liu H, Storrick E, Zahrieh D, Le-Petross HC, Jung SH, Zekan P, Kemeny MM, Charlamb JR, Wang LX, Unzeitig GW, Johnson CS, **Garber JE,** Marshall JR, Bedrosian I. The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. Cancer Prev Res (Phila). 2021 Jul;14(7):753-762. doi: 10.1158/1940-6207.CAPR-20-0581. Epub 2021 Apr 13. PMID: 33849913

296. Reilly CR, Myllymäki M, Redd R, Padmanaban S, Karunakaran D, Tesmer V, Tsai FD, Gibson CJ, Rana HQ, Zhong L, Saber W, Spellman SR, Hu ZH, Orr EH, Chen MM, De Vivo I, DeAngelo DJ, Cutler C, Antin JH, Neuberg D, **Garber JE,** Nandakumar J, Agarwal S, Lindsley RC. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 Sep 9;138(10):898-911. doi: 10.1182/blood.2021011075. PMID: 34019641

297. Xu J, Keenan TE, Overmoyer B, Tung NM, Gelman RS, Habin K, **Garber JE,** Ellisen LW, Winer EP, Goss PE, Yeap BY, Chabner BA, Isakoff SJ. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Res Treat. 2021 Oct;189(3):641-651. doi: 10.1007/s10549-021-06292-7. Epub 2021 Aug 20. PMID: 34417675 Clinical Trial.

298. Guzmán-Arocho YD, Rosenberg SM, **Garber JE,** Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2021 Oct 26. doi: 10.1038/s41416-021-01597-2. Online ahead of print. PMID: 34703009

299. Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, Achatz MI, Savage SA, Weitzel JN, **Garber JE,** Hainaut P, Malkin D. Analysis of the Li-Fraumeni

Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol. 2021 Oct 28:e214398. doi: 10.1001/jamaoncol.2021.4398. Online ahead of print. PMID: 34709361

300. Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, **Garber JE,** Goggins MG, Maitra A, Syngal S. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prev Res (Phila). 2021 Nov;14(11):1021-1032. doi: 10.1158/1940-6207.CAPR-20-0642. Epub 2021 Oct 8. PMID: 34625409 Clinical Trial.

301. Jalloul N, Gomy I, Stokes S, Gusev A, Johnson BE, Lindeman NI, Macconaill L, Ganesan S, **Garber JE,** Khiabanian H. Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precis Oncol. 2021 Nov 17;5:PO.21.00279. doi: 10.1200/PO.21.00279. eCollection 2021. PMID: 34820595

302. Rana HQ, Koeller DR, Schwartz A, Manning DK, Schneider KA, Krajewski KM, Choueiri TK, Lindeman NI, **Garber JE,** Ghazani AA. Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. Eur J Med Genet. 2021 Dec;64(12):104359. doi: 10.1016/j.ejmg.2021.104359. Epub 2021 Oct 8. PMID: 34628056

303. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, **Garber JE,** Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol. 2021 Dec 1:S0302-2838(21)02139-4. doi: 10.1016/j.eururo.2021.10.036. Online ahead of print. PMID: 34863587

304. Bychkovsky BL, Lo MT, Yussuf A, Horton C, Richardson M, LaDuca H, **Garber JE,** Rana HQ. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics. Cancer. 2021 Dec 7. doi: 10.1002/cncr.34056. Online ahead of print. PMID: 34875721

<u>Non-Peer Reviewed Scientific Publications or medical publications/materials in print or other media</u>

Proceedings of meetings

1. **Garber JE**, Li FP. Study of reproductive outcomes. Proceedings of the Fifth National Conference on Human Values and Cancer, 1987:45-8. American Cancer Society, New York, NY.

2. Henderson IC, **Garber JE**, Breitmeyer JB, Hayes DF, Harris JR. Comprehensive management of disseminated breast cancer. Proceedings of the National Conference on Breast Cancer. Cancer 1990; 66:1439-48.

3. Mai PL, Malkin D, **Garber JE**, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF Jr, Savage SA. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012 Oct;205(10):479-87; 205:479-87.

Reviews, chapters, monographs and editorials

1. **Garber JE**. Long term follow-up of children exposed in utero to antineoplastic agents. Sem Oncol. 1989; 16:437-44.

2. **Garber JE**, Henderson IC, The use of chemotherapy in metastatic breast cancer. Hematol/Oncol Clin No America. 1989; 3:807-21.

3. Henderson IC, Hayes DF, Parker LM, Love S, **Garber JE**, Recht A, Breitmeyer JB, Harris JR, Canellos GP. Adjuvant systemic therapy for patients with node-negative tumors. Cancer 1990; 6 5:2132-47.

4. **Garber JE**, Li, FP. The value of studying cancer families [editorial]. J Clin Oncol 1990; 8:574.

5. **Garber JE**. Familial aspects of breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast Diseases. Philadelphia: JB Lippincott Co., 1991; 142-52.

6. **Garber JE**, Henderson IC, Love SM, Gelman RS. Management of high risk groups. In: Harris JR, Helman S, Henderson IC, Kinne DW, eds. Breast Diseases. Philadelphia: JB Lippincott Co., 1991; 152-63.

7. Li FP, **Garber JE**, Friend SH, Strong LC, Patenaude AF, Juengst ET, Reilly PR, Correa P, Fraumeni JF Jr. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. [editorial]. J Natl Cancer Inst. 1992; 84:1156-60.

8. **Garber JE**. The role of genetic counseling in the management of long term survivors of childhood cancers. In: Bricker JT, Green DM, D'Angio GJ. Editors, Cardiac toxicity after treatment for childhood cancer. New York: Wiley-Liss, 1993; 121-9.

9. Li FP, **Garber JE**. Commentary: Gene for familial breast and ovarian cancer. Lancet 1993; 341:1060-1.

10. Weber BL, **Garber JE**. Family history and breast cancer: Probabilities and possibilities [editorial]. JAMA 1993; 70:1602-3.

11. **Garber JE**, Diller L. Screening children at genetic risk of cancer. Cur Opin Pediatr 1993; 5:712-15.

12. **Garber JE.** Markers of risk for human malignancies. Hematol Oncol Clin North Am 1994; 8:471-83.

13. **Garber JE**, Patenaude AF. Ethical, Social and Counseling Issues. Cancer Genetics. Cancer Surveys. 1995; 5:381-97.

14. Schneider, KA, Patenaude AF, **Garber JE**. Testing for cancer genes: decisions, decisions. Nat Med 1995; 1:302-3.

15. Biesecker BB, **Garber JE**. Testing and counseling adults for heritable cancer risk. J Natl Cancer Inst 1995; 17:115-18.

16. **Garber JE,** Smith BL. Management of the High Risk and the Concerned Patient in Breast Diseases. In: Harris JR, Hellman SE, Lippman ME, Morrow M., eds. Diseases of the Breast 1996; 9:323-34.

17. Weber BL, **Garber JE**. Genetics of Breast Cancer. In: Breast Diseases. Harris JR, Hellman SE, Lippman ME, Morrow M., eds. Diseases of the Breast 1996; 2:168-85.

18. Burke W, Kahn MJE, **Garber JE,** Collins FS. "First Do No Harm" Also applies to cancer susceptibility testing [editorial]. Cancer J Sci Am 1996; 2:250.

19. **Garber JE**, Schrag D. Testing for inherited cancer susceptibility [editorial]. JAMA 1996; 275:1928-9.

20. Olopade OI, Offit K, **Garber JE**. Genetic testing for susceptibility to cancer. Task Force on Cancer Genetics Education. JAMA 1998; 279:1612-13.

21. **Garber J.** Inherited breast cancer: increasingly familiar territory. J Clin Oncol 1998; 16:1639-41.

22. Partridge AH, **Garber JE**. Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol 2000; 27:712-26.

23. DiGianni LS, **Garber JE,** Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 2002; 20:34S-8S.

24. **Garber JE**. Breast cancer screening: a final analysis? [editorial]. CA Cancer J Clin. 2003;53(3):138-4.

25. **Garber JE,** Syngal S. One less thing to worry about: the shrinking spectrum of tumors in BCRA founder mutation carriers [editorial]. J Natl Cancer Inst 2004; 7:962-3.

26. **Garber JE**, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? [editorial]. J Clin Oncol. 2004; 22:978-80.

27. **Garber JE**, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005; 23:276-92.

28. Masciari S, **Garber JE**, Quality or quantity in the management of hereditary ovarian cancer risk: is it really a trade-off? [editorial]. J Clin Oncol 2005; 23:6817-19.

29. **Garber JE**. Hereditary Cancer Syndromes in Principles of Genetic Screening. Von Roenn J, Brawley O, Khuri F, Rock C. Eds. American Society of Clinical Oncology: O Curriculum: Cancer Prevention. ASCO 2007; 12:1-30.

30. Offit K, **Garber JE**. Time to check CHEK2 in families with breast cancer? [editorial] J Clin Oncol 2007; 26:519-20.

31. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, **Garber JE**, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008; 26:806-13.

32. Rainville I, **Garber JE**. Familial database online. Lancet 2008 ; 925-6.

33. Schrader KA, Masciari S, Boyd N, Wiyrik S, Kaurah P, Senz J, Burke W, Lynch HT, **Garber JE**, Huntsman DG. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 2008; 7:73-82.

34. Schneider BP, Winer EP, Foulkes WE, **Garber J**, Perou CM, Richardson A. Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14:8010-18.

35. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, **Garber JE**, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research issues affecting preoperative systemic therapies. J Clin Oncol, 2008;26:806-13.

36. **Garber JE**. BRCA 1 / 2 – associated and sporadic breast cancers: fellow travelers or not? [editorial] Cancer Prev Res. 2009; 2:100-3.

37. **Garber JE**, Golshan M. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side. [editorial] J Clin Oncol. 2009; 27:5862-4.

38. Balmana J, Domchek SM, Tutt A, **Garber JE**. Stumbling blocks on the path to personalized medicine in breast cancer: The case of PARP inhibitors for BRCA1/2-Associated Cancers. [commentary] Cancer Discovery. 2011; 1:29-34.

39. Freedman RA, **Garber JE.** Family cancer history: healthy skepticism required. [editorial] J Natl Cancer Institute. 2011; 103:776-7.

40. Issa JP, **Garber JE**. Time to think outside the box. Cancer Prev Res. 2011;4 (1):6-8.

41. Balmaña J, Domchek SM, Tutt A, **Garber JE**. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 2011; 1:29-34.

42. Freedman RA, **Garber JE**. Family cancer history: healthy skepticism required. J Natl Cancer Inst. 2011; 103:776-7.

43. Tung N, **Garber JE**, Lincoln A, Domchek SM. Frequency of Triple-Negative Breast Cancer in BRCA1 Mutation Carriers: Comparison Between Common Ashkenazi Jewish and Other Mutations. J Clin Oncol. 2012; 30:4447-8.

44. Domchek SM, Bradbury A, **Garber JE**, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013 Apr 1;31(10):1267-70. 2013; 31:1267-70.

45. Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 2014 Jun;35(6):654-62.

46. Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, **Garber JE**, Offit K, Robson ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016 Sep;13(9):581-8.

47. Tung NM, **Garber JE**. Reply to S.M. Sorscher and M.J. Hall et al. J Clin Oncol. 2016 Dec;34(34):4187-4188.

48. Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, **Garber JE**. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 2016 Dec;160(3):393-410. Epub 2016 Oct 12.

49. **Garber JE.** THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. Trans Am Clin Climatol Assoc. 2016;127:127-139.

50. Peters ML, **Garber JE,** Tung N. Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecol Oncol. 2017 Jul;146(1):205-214. Epub 2017 Apr 25. Review.

51. Kratz CP, Achatz MI, Brugières L, Frebourg T, **Garber JE**, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017 Jun 1;23(11):e38-e45. Review.

52. Mazzola E, Coopey SB, Griffin M, Polubriaginof F, Buckley JM, Parmigiani G, **Garber JE**, Smith BL, Gadd MA, Specht MC, Guidi A, Hughes KS. Reassessing risk models for atypical hyperplasia: age may not matter.Breast Cancer Res Treat. 2017 Sep;165(2):285-291. Epub 2017 Jun 6. Review.

53. Coopey SB, Kartal K, Li C, Yala A, Barzilay R, Faulkner HR, King TA, Acevedo F, **Garber JE,** Guidi AJ, Hughes KS. Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?. Breast Cancer Res Treat. 2019 May;175(1):1-4. doi: 10.1007/s10549-018-05117-4. Epub 2019 Jan 21. Review. PubMed PMID: 30666539.

54. Gomy I, **Garber JE.** One step forward, two steps backward. Genet Med. 2020 Feb;22(2):441-442. doi: 10.1038/s41436-019-0660-5. Epub 2019 Oct 3. PubMed PMID: 31578472.

Clinical Guidelines and Reports

1. Statement of the American Society of Human Genetics on Genetic Testing for Breast and Ovarian Cancer Predisposition, The American Society of Human Genetics Ad Hoc Committee. AJHG 1994; 55: i-iv.

2. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996; 14:1730-6.

3. American Society of Clinial Oncology Curriculum: Cancer Genetics and Cancer Predisposition Testing, (Vol I) Basic Genetics, Mutation Detection Methods, Cancer Risk Assessment, Genetic Testing Process, Ethical, Legal, and Social Issues. (Vol II) Colorectal Cancer, Breast/Ovarian/Pediatric/ Multiple Endocrine, Neoplasia Type 2 Melanoma. ASCO 1998.

4. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21:2397-406

5. The CRICO/RMF Breast Care Management Algorithm: Risk Assessments and Potential Interventions, CRICO 2003.

6. American Society of Clinical Oncology Statement on Cancer Prevention, Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, **Garber JE,** Hawk E, Ganz PA, Somerfield MR; Writing Committee of the ASCO Cancer Prevention. Cancer

Prevention and the American Society of Clinical Oncology. J Clin Oncol 2004; 22:3848-51.

7. The CRICO/RMF Breast Care Management Algorithm: Risk Assessments and Potential Interventions, CRICO 2008.

8. Visvanathan K, Banu A, Brown P, Chlebowski R, Col N, Collyar D, Cuzick J, **Garber J**, Hagerty K; Hurley P, Kramer B, Morrow M, Pritchard K, Ropka M, Runowicz C, Vogel V, Wade JL; American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. American Society of Clinical Oncology**.** J Clinical Onc 2009; 27:3235-58**.**

9. Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson, ME, Wollins DS, **Garber JE**, Brown P, Kramer BS. American Society of Clinical Oncoogy Policy Statement: The role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 2009; 27:986-98.

10. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MP, Dempsey PJ, Farrar WB, Flemining I, **Garber JE,** Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yaneeklov T; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009; 7:1060-96.

11. Levy DE, **Garber JE**, Shields AE. Guidelines for genetic risk assessment of hereditary Breast and ovarian cancer: early disagreements and low utilization. J Gen Intern. 2009; 24:822-8.

12. Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, **Garber JE**, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.

13. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, **Garber JE**, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

14. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, **Garber JE**, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM,

Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

15. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, **Garber JE**, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017 Jan;15(1):9-20.

16. Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, **Garber JE**, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389. doi: 10.6004/jnccn.2018.0083. PubMed PMID: 30442736.

17. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, **Garber JE,** Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020 Apr;18(4):380-391. doi: 10.6004/jnccn.2020.0017. PubMed PMID: 32259785.

NARRATIVE

The major focus of my career has been the development of Clinical Cancer Genetics as a new area of specialization within oncology. I am the Chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute. In 1994, I founded the Dana-Farber Cancer Risk and Prevention Clinic, one of the first devoted to the identification and management of individuals at highest cancer risk. The Clinic has served as a major referral center for clinical care and genetic, epidemiologic, and related research, and clinical trials of cancer preventive interventions and cancer genetic counseling model and formed the basis for the center. We provide testing in our clinic, and across the Institute, including all ovarian cancer patients, and most recently all pancreatic cancer and high-grade prostate cancer patients, as well as pediatric cancer. We also provide testing to all Dana Farber satellites and affiliated institutions.

In order to foster the incorporation of cancer genetics into clinical practice I have played a major role in the development of national guidelines in genetics (American College of Medical Genetics) and medical oncology (American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network). In addition, I have organized meeting sessions and courses including co-directing the annual Harvard Breast Cancer CME course, and collaborated on the

development of educational slide sets and curricula in cancer genetics and prevention for health professionals (ASCO, American Cancer Society).

My research activities include the study of breast cancer risk assessment and communication, breast cancer genetics, and pharmacogenetics. I lead epidemiologic, cancer surveillance and risk reduction studies in hereditary cancers, including breast and ovarian cancers, pediatric cancers and sarcomas. I have been continuously funded by the NIH for this work and have had additional funding from the DoD and private foundations. More recently my research has expanded to the study of basal-like breast cancer, the most common form in women with BRCA1 mutations. Our first neo-adjuvant trial of cis-platinum in these patients based on the role of BRCA1 in DNA repair demonstrated a significant complete response rate and has led to a series of trials, including a phase III international, multicenter trial examining the role of the PARP inhibitor Olaparib in the adjuvant treatment of BRCA1/2-associated breast cancers, the initial publication from which was published in the NEJM in 2021. I have been recognized with elected membership in the American Society of Clinical Investigation, the American Association of Physicians, and the National Academy of Medicine (the former IOM). I have been elected as a Fellow of the AACR Academy and appointed as a Fellow of the American Society of Clinical Oncology. I have received the Joseph H. Burchenal Award from AACR, the American Cancer Society Award from ASCO and the Brinker Award in Clinical Research from the Susan G. Komen for the Cure, among others. I also play significant roles in the scientific community. I am a regular reviewer for several journals and have served as senior editor for two and on the editorial board of 3 others. I served a term as President of AACR (4/2011 – 3/2012), one on the NCI Board of Scientific Counselors, a term as a presidential appointee to the National Cancer Advisory Board, and a member of the NIH Council of Councils. I was the inaugural president of the AACR Academy. I am the Scientific Director of the Breast Cancer Research Foundation, the largest private funder of breast cancer research in the world and serve on the steering committee of the LiFE Consortium for Li Fraumeni Syndrome. I am a member or chair of the Data Safety Monitoring Committees of several international breast cancer clinical trials and have chaired numerous grant review panels in cancer research and training.

I am also active in the teaching of medical students, housestaff, and fellows as well as practicing physicians and the lay public.